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H u m a n keratinocytes are known to kill Candida albi-
cans in vitro, but the mechanism o f Willing is not yet 
understood. Here, w e demonstrate that spontaneous, 
ultraviolet-B-light-induced, (X-melanocyte-stimulat-
ing-hormone- induced, and interleukin-8-induced 
Candida killing by keratinocytes can be inhibited with 
mannan and mannosylated bovine serum albumin 
(Man-BSA). A polyclonal goat serum raised against 
the human macrophage mannose receptor stained 
suprabasal keratinocytes, but n o staining was 
observed on keratinocytes with a monoclonal anti-
b o d y (mAb 1 5 ) specific for the human macrophage 
mannose receptor. Mannose-affinity chromatography 
o f keratinocyte extract isolated a 200 kDa protein, 
and on the Western blot the goat antiserum reacted 
wi th a 200 kDa protein. In radioligand binding 
studies, the binding o f l z s I -Man-BSA t o h u m a n kera-
tinocytes was inhibited by mannan in a concentra-
t ion-dependent manner. Analysis o f the binding 
revealed a single class keratinocyte mannose receptor 
wi th a K b o f 1.4 X 10~® M and a B ^ o f 1 X 104 
binding sites per cell. The binding o f 1 2 5I-Man-
B S A t o keratinocytes proved to be t ime-dependent , 
acid-precipitable, and C a 2 + - and trypsin-sensitive. 
After trypsinization the receptors underwent a rapid 
recovery at 37°C. These results demonstrate the pres-
ence o f mannose receptor o n human keratinocytes, 
and its active involvement in the killing o f Candida 
albicans. Key words: antimicrobial activity/Candida infec-
tion/epidermis/skin. J Invest Dermatol 117:205-213, 2001 
In both experimental and naturally occurring cutaneous Candida albicans infections, the infecting Candida albicans organisms are confined to the upper portion of the epidermis (Kirkpatrick et al, 1971; Scherwitz, 1982; Sohnle and Hahn, 1992). Deep or systemic Candida 
infections are rare in patients with chronic mucocutaneous 
candidiasis, despite extensive superficial infections (Ray and 
Wuepper, 1978; Kauffman et al, 1981). The formation of 
neutrophilic infiltrates in the epidermis and epidemial hyperpro-
liferation are characteristic cutaneous changes in Candida albicans 
infections of the skin. Each of these cutaneous responses has been 
suggested to be important for the defense against superficial fungal 
infections (Sohnle and Kirkpatrick, 1978; Sohnle and Hahn, 1989). 
Although polymorphonuclear (PMN) leukocytes easily phago-
cyrize Candida albicans in vitro, ultrastructural examination of 
Candida-infected skin failed to show fungal elements in regions 
of microabscesses (Scherwitz, 1982). On the other hand, in that 
same study, the majority of the fungal cells were found among 
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epithelial cells of the stratum comeum and they could not be 
detected in noncornified cells of the malphigian layer. In a more 
recent investigation using cyclophosphamide-treated mice it was 
shown that even in the absence of epidermal neutrophil infiltrates 
Candida albicans is confined to the epidermis. Removal of the 
epidermis by scraping prior to inoculation with the yeast, however, 
resulted in Candida pseudohyphae invasion of the dermis, 
indicating that suprabasal keratinocytes may play a role in the 
defense against cutaneous Candida infection (Halm and Sohnle, 
1988). Vaginal epithelial cells of both rodents and macaques have 
recently been shown to be predominandy responsible for innate 
immunity against yeast cell colonization (Steele et al, 1999a, b). 
In previous work we have shown that epidermal cells have direct 
candidacidal activity and this activity can be increased through 
stimulation of epidermal cells with ultraviolet (UV) light (Csato 
et al, 1986, 1987), a-melanocyte stimulating hormone (a-MSH) 
(Csato et al, 1989), and intedeukin-8 (IL-8).1 IL-1, prostaglandin E2 
(PGE2), and platelet-activating factor have also been demonstrated 
to be involved in Candida killing by human epidermal cells (Csato 
et al, 1990), but the mechanism of killing remains unknown. 
Mononuclear phagocytes are believed to play an important role 
in combating fungal infections. Optimal phagocytosis of Candida 
albicans requires opsonization, but unopsonized yeast can also be 
internalized by macrophages through the mannose receptor 
(Karbassi et al, 1987). The major components of the cell wall of 
Candida are mannan (an a-linked polymer of mannose), glucan (a 
p-linked branched chain polysaccharide of glucose), and chitin (a 
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Figure 9. B i n d i n g o f 1 2 5 I -Man-BSA to h u m a n kerat inocytes at 
37°C is drastically decreased after acetic acid (pH 3) treatment . 
The binding of 1 2 5I-Man-BSA at 37°C was also measured after a 3 min 
treatment with acetic acid (pH 3). T h e mannan-specific binding, 
calculated as the difference between the total and the mannan-
independent binding, is shown by the black bars. T h e mannan-specific 
binding after acetic acid treatment is demonstrated by the gray bars (acid 
stable). The difference between the total and the acid-stable binding 
represents the acid-labile binding (white bars). Error bars are the means of 
the results of four separate experiments ± SEM. 
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Figure 11. Limited proteolys is reduces ~ I - M a n - B S A binding to 
h u m a n keratinocytes. Trypsin treatment at 37°C was used to assess the 
sensitivity of the K c M R to proteolytic digestion. I 2 5 I -Man-BSA binding 
was measured both in the presence and in the absence of mannan. 
Incubations were stopped and binding was evaluated after an incubation 
period of 0, 10, 60, or 120 min wi th 10 | ig per ml trypsin. T h e 
mannan-specific 1 2 5 I -Man-BSA binding underwent significant t ime-
dependent decrease. Error bars represent means ± SEM, n = 4; the 
asterisks denote significant decreases (*p < 0.05 and **p < 0.001) on 
trypsin-treated cells relative to cells wi thout trypsin treatment. 
Control EGTA treatment 
Figure 10. Ca deplet ion inhibits T - M a n - B S A b i n d i n g to 
h u m a n keratinocytes . In the radioligand binding assay, human 
keratinocytes were incubated with 1 2 5 I -Man-BSA in the presence or 
absence of 10 m M E G T A for 30 min at 37°C. T h e figure shows the 
mannan-specific binding. Error bars represent means ± SEM, n — 4; the 
asterisk denotes a significant decrease (p < 0.01) for cells treated with 
E G T A compared wi th cells without E G T A treatment. 
a n d ricin, a n d t h e u p t a k e o f IgE, a n d t h e y are i n v o l v e d i n t h e 
phagocy tos i s o f v a r i o u s m i c r o o r g a n i s m s ( C h u n g et al, 1984 ; S p e e r t 
et al, 1988; R i j k e n et al, 1990; M a g n u s s o n a n d B e r g , 1993 ; 
R i c h a r d s o n et al, 1993 ; Sa to and B e u t l e r , 1993) . M a r o d i et al 
r e p o r t e d tha t m o n o c y t e - d e r i v e d m a c r o p h a g e s are ab le t o inges t a n d 
kill Candida t h r o u g h t h e m a n n o s e r e c e p t o r ( M a r o d i et al, 1991a ; 
1991b) . T h e expres s ion o f the surface M M R can b e d o w n r e g u l a t e d 
d u r i n g m a c r o p h a g e ac t iva t ion w i t h Bacillus-Calmette-Guerin 
( E z e k o w i t z et al, 1981) o r w i t h l i popo lysaccha r ide a n d p h o r b o l 
esters ( S h e p h e r d et al, 1990) , a n d u p r e g u l a t e d b y co r t i cos t e ro id s , 
P G E 2 , a n d I L - 4 (Schre ibe r et al, 1990 ; Stahl , 1990 ; S t e i n et al, 
1992) . A l t h o u g h i n t e r f e r o n y ( IFN-y ) t r e a t m e n t dec reases t h e 
n u m b e r o f m a n n o s e r ecep to r s o n t h e m a c r o p h a g e s , t h e i r capac i ty 
f o r m a n n o s e - r e c e p t o r - m e d i a t e d phagocy tos i s is i nc reased , sugges t -
i n g a d i ssoc ia t ion b e t w e e n t h e effects o f I F N - y o n t h e n u m b e r s o f 
r e c e p t o r s expressed o n the surface a n d t h e f u n c t i o n o f these 
r e c e p t o r s ( M a r o d i et al, 1993; 1994) . 
Figure 12. Flow c y t o m e t r i c de tec t i on o f h u m a n K c M R o n freshly 
separated h u m a n kerat inocytes after trypsin treatment . Cells were 
stained with the goat ant i -human M M R antiserum and analyzed by flow 
cytometry. For isotype control, n o n - i m m u n e goat serum was used. T e n 
minutes after the trypsin treatment 32.5% of the cells already exhibited 
positive staining (FL1, thick line) relative to the isotype control (FL1, thin 
line), and the A M C F was 8.36, indicating that the K c M R on the 
keratinocytes can recover very rapidly after trypsinization. 
I n earl ier s tudies, w e h a v e s h o w n tha t Candida albicans k i l l ing by 
h u m a n ke ra t inocy te s c a n b e e n h a n c e d b y U V B l ight , a - M S H 
(Csa to et al, 1987; 1989) , a n d I L - 8 . 1 T h i s s t u d y has r evea l ed t h a t 
m a n n a n and M a n - B S A are v e r y e f fec t ive i n h i b i t o r s o f b o t h 
s p o n t a n e o u s and U V B - , a - M S H - , a n d I L - 8 - s t i m u l a t e d Candida 
ki l l ing b y freshly separa ted k e r a t i n o c y t e s , i n d i c a t i n g t h a t m a n n o s e -
b i n d i n g s t ruc tures are p r e s e n t o n t h e k e r a t i n o c y t e s a n d p lay a ro l e 
'Kemeny L, Kenderessy AS, Arenberger P, Peter R U , Dobozy A, 
Ruzicka A: Interleukin-8 induced chetnotaxis and increased Candida 
albicans killing activity of normal human epidermal cells. Arch Dermatol Res 
284:26, 1992 (abstr.) 
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Figure 4. S D S - P A G E o f the h u m a n K c M R . The eluates wi th the 
two highest protein contents (lanes 2 and 3) from epoxy-activated 
mannose-Sepharose 6B column were concentrated and subjected to 
SDS-PAGE under non-reducing conditions. Proteins were stained wi th 
silver. The separation revealed a single protein with a mass of —200 kDa 
(arrow). Lane 1: molecular weight marker. 
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Figure 5. Western b lo t t ing o f kerat inocyte cell lysates. H u m a n 
keratinocyte (lane 1) and the human immortalized keratinocyte cell line 
H a C a T (lane 2) cell extracts were blotted to nitrocellulose filter. T h e 
arrow indicates the position of an —200 kDa protein recognized by the 
goat anti-human M M R antiserum. Lane 3: molecular weight marker. 
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Figure 6. C o m p e t i t i o n study o f 1 2 T - M a n - B S A binding to h u m a n 
keratinocytes. Cells were incubated at 4 °C for 90 min with 1 2 5 I -Man-
BSA (6 X 1(J4 cpm per well) and wi th increasing concentrations of 
unlabeled ligand (mannan) in the range 10-3000 | ig per ml. Mannan 
dose-dependently inhibited the 1 2 s I -Man-BSA binding to freshly 
separated keratinocytes. Error bars represent the means ± SEM of the 
results of six separate experiments. 
p e r c e n t a g e o f pos i t ive cells a n d A M C F ( the m e a n c h a n n e l 
fluorescence o f cells s ta ined w i t h t h e goa t i m m u n e s e r u m m i n u s 
t h e m e a n c h a n n e l fluorescence o f cells s ta ined w i t h t h e n o n -
i m m u n e goa t s e r u m ) s h o w e d a rap id , rime-dependent i nc rea se in 
K c M R re - exp re s s ion o n ke ra t i nocy t e s . A f t e r t h e shor tes t (10 m i n ) 
i n c u b a t i o n , 3 2 . 5 % o f t h e cells a l ready e x h i b i t e d pos i t ive s t a in ing 
re la t ive t o t h e i so type c o n t r o l , a n d t h e A M C F w a s 8 .36 ( F i g 12) , 
i n d i c a t i n g tha t K c M R o n t h e k e r a t i n o c y t e s can r e c o v e r v e r y 
2 4 
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Figure 7. Saturation study o f 1 2 5 I - M a n - B S A b i n d i n g to h u m a n 
kerat inocytes . Cells were incubated wi th increasing concentrations of 
1 2 5 I -Man-BSA (10 5 -2 X 10" cpm per well). Mannan-independent 
binding was detennined in the presence of 3 m g per ml unlabeled 
mannan. Mannan-specific binding was defined as the difference between 
the total and the mannan- independent 1 2 5I-Man-BSA binding. Each 
assay was carried out in duplicate in three separate experiments. The inset 
shows the Scatchard analysis of the data: K D - 1.4 X 10 - 8 M, and J3nccI 
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Figure 8. Radio l igand b ind ing o f h u m a n kerat inocytes at 37°C. 
T h e binding of l S i - M a n - B S A (4 X 10* cpm in each well) was 
measured at 37°C after 10, 20, or 3 0 min. The total binding was t ime-
dependent . T h e difference between the total (solid line) and the mannan-
independent activity (measured in the presence of 3 m g per ml unlabeled 
mannan) (dashed line) is shown by the dotted cuwe and represents the 
mannan-specific binding. Error bars are the means of the results of four 
separate experiments ± SEM. 
rap id ly a f t e r t ryps in iza t ion . F o l l o w i n g p r o l o n g e d i n c u b a t i o n , w e 
d e t e c t e d time-dependent increases in b o t h t h e n u m b e r o f 
m a n n o s e - r e c e p t o r - p o s i r i v e cells (30 m i n , 4 9 . 3 8 % ; 6 0 m i n , 
5 6 . 1 8 % ; 1 2 0 n u n , 65 .81%) a n d A M C F (30 m i n , 12 .47 ; 6 0 m i n , 
14 .08 ; 1 2 0 m i n , 17 .05) . 
D I S C U S S I O N 
T h e m e c h a n i s m o f t h e h o s t d e f e n s e against p a t h o g e n i c m i c r o -
o r g a n i s m s i n t h e skin is n o t c o m p l e t e l y u n d e r s t o o d . W e d e m o n -
s t ra ted ear l ier tha t h u m a n e p i d e m i a l cells e x e r t cand idac ida l ac t iv i ty 
m e d i a t e d b y k e r a t i n o c y t e s (Csa to et al, 1 9 8 6 , 1987) . 
A p la sma m e m b r a n e r e c e p t o r f o r l igands w i t h t e r m i n a l m a n n o s e 
res idues , t h e M M R , has a l ready b e e n we l l d e f i n e d o n h u m a n 
m a c r o p h a g e s (Stahl, 1990) . M a n n o s e r e c e p t o r s can m e d i a t e t h e 
e n d o c y t o r i c c l ea rance o f g l y c o p r o t e i n s , i n c l u d i n g e n z y m e s from 
n e u t r o p h i l s , t i s sue - type p l a s m i n o g e n ac t iva to r , g lucoce reb ros idase , 
VOL. 117, NO. 2 AUGUST 2001 ANT1- CANDIDA ACTIVITY OF HUMAN KERATINOC.YTES 209 
Figure 2 . Candida albicans adheres to the 
surface o f keratinocytes . Fluorescence micro-
scopy analysis demonstrated that keratinocytes 
wi th moderate autofluorescence bound F I T C -
conjugated, round-shaped intensely fluorescing 
Candida cells following a 120 min incubation 
(arrow) (a). Incubation wi th 3 mg per ml mannan 
reduced the number of keratinocytes that bound 
Candida (b). Candida attachment was quantitated 
by flow cytometry (c, d). Non-adherent Candida 
cells were gated out on the basis of their light-
scatter characteristics. T h e abscissa depicts yeast 
cell fluorescence intensity on a logarithmic scale 
and the ordinate gives the relative cell number . 
(A) Autofluorescence of keratinocytes wi thout 
FITC-labeled yeasts; (B) fluorescence of Candida 
cells adhered to the surface of keratinocytes. 
FITC-conjugated Candida albicans cells were 
incubated wi th freshly separated keratinocytes for 
120 min. After the incubation 16% of the 
keratinocytes were FITC-positive, indicating the 
adherence of the yeasts to the keratinocytes (c). 
Following mannan (3 mg per ml) pretreatment of 
human keratinocytes for 60 min prior to 
incubation wi th Candida albicans, 6% of 
keratinocytes were FITC-positive (d). 
Figure 3. Sect ions o f normal h u m a n skin 
stained wi th antibodies against the h u m a n 
M M R . Wi th the monoclonal antibody (mAbis) a 
few individual cells showed positive staining in 
the dermis (arrow) (a). T h e polyclonal antibody 
stained not only the dermal cells but also the 
keratinocytes in the epidermis (b). T h e staining 
was more pronounced on the suprabasal cells and 
the pattern indicated a membrane localization. 
Scale bar. 20 pan. 
that most of the bound 125I-Man-BSA remained cell-surface-
associated and only a very small portion was internalized. 
Effect of Ca2+ depletion on radioligand binding To 
determine the Ca" dependence of carbohydrate recognition, we 
examined the effect of EGTA, a Ca2+-chelating agent, on the 
ligand binding. In the radioligand binding assay, human 
keratinocytes (5 X 105) were incubated with Y25I-Man-BSA (4 
X 106 cpm per well) in the presence or absence of 10 raM EGTA 
for 30 min at 37°C. As shown in Fig 10, EGTA almost completely 
inhibited the radioligand binding to the keratinocytes, suggesting 
that the binding was Ca2+-sensitive. 
Effect of trypsin on 125I-Man-BSA binding The trypsin 
sensitivity of the mannose-binding sites was investigated by 
incubating the freshly separated human keratinocytes with 10 (Xg 
per ml of trypsin at 37°C for different time intervals prior to the 
radioligand binding study. In line with previous observations 
involving the use of macrophages (Stahl, 1990), the binding sites 
appeared to be highly sensitive to trypsin treatment. Trypsin 
induced a time-dependent loss of radioligand binding (Fig 11). 
Incubation of cells with trypsin for 120 min resulted in a loss of 
>90% of the radioligand binding. 
Flow cytometric analysis of KcMR Although the keratino-
cytes were exposed to trypsin during cell preparation in our 
Candida killing and 12SI-Man-BSA binding assays, the results of the 
experiments indicated that the receptors recovered quickly. Kang 
and Schlesinger also found that the removal of surface-expressed 
MMR activity by trypsin incubation at 4°C was followed by a fast 
(10 min) recovery of the receptor activity at 37°C (Kang and 
Schlesinger, 1998). To determine the recovery of the KcMR after 
trypsinization during the preparation of a cell suspension, freshly 
separated keratinocytes were incubated in PBS at 37°C for 10, 30, 
60, or 120 min after trypsin exposure, and then stained with the 
goat polyclonal serum and analyzed by flow cytometry. Both the 
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Figure 1. Mannan and M a n - B S A inhibit Candida kil l ing by 
keratinocytes. (a) Mannan, (h) Man-BSA. Spontaneous and stimulated 
( a - M S H , IL-8, and UVB) Candida killing is represented by gray bars. 
Addition of 100 g g per ml mannan or 100 Jig per ml Man-BSA (while 
bars) or 500 Jig per ml mannan or 500 Jig per ml Man-BSA (black bars) 
to the killing assay resulted in a significant reduction of both the 
spontaneous and the stimulated Candida albicans killing. Error bars 
represent the means ± SEM of the results of six separate experiments. 
Candida killing activity is expressed as the percentage of killed yeast cells. 
An asterisk denotes significant difference (p < 0.05). 
by the addition of Gal-BSA, suggesting that the inhibitory effect of 
mannan was specific (9.7 ± 1.2% and 9.3 ± 2.3% Candida cell 
death, respectively, in the presence or absence of 300 pg per ml 
Gal-BSA). Data were obtained from two independent experiments 
performed in triplicate. 
Mannan did not exert a non-specific protective effect on 
ciclopirox-olamine-induced Candida albicans cell death. The addi-
tion of 5 mg per ml ciclopirox olamine killed the total number of 
Candida cells both in the presence and in the absence of mannan. In 
the presence of mannan 6.3 ± 0.6%, and in the absence of mannan 
6.7 ± 0.6%, of yeast cells were killed by 2.5 mg per ml ciclopirox 
olamine. These results were obtained from two independent 
experiments performed in triplicate. 
To probe the hypothesis that Man-BSA may interfere with the 
killing of Candida by cells that do not express mannose-binding 
receptors, we studied the killing of Candida albicans by peripheral 
blood granulocytes. There was no difference in the killing of 
Candida albicans opsonized with 2.5% normal human serum in the 
presence or absence of Man-BSA (45 ± 7% and 39 ± 5%, 
respectively, in the presence or absence of 1 mg per ml Man-BSA 
after a 30 min incubation). These data were obtained from four 
independent experiments performed in triplicate. 
Candida albicans adheres to human keratinocytes and this 
adherence is inhibited by mannan To visualize the 
adherence of Candida albicans to keratinocytes, FITC-conjugated 
yeast cells were incubated with keratinocytes. Figure 2(a) shows 
that FITC-positive Candida cells attached to the surface of 
keratinocytes. The addition of 3 mg per ml mannan produced a 
significant decrease in the number of keratinocytes that bound 
FITC-conjugated Candida (Fig 2b). Candida adherence was 
quantitated by means of flow cytometric analysis. Unattached 
FITC-labeled Candida cells were electronically gated out on the 
basis of light scattering analysis. After a 120 min incubation 16% of 
the keratinocytes were FITC-positive, indicating the adherence of 
the yeasts to the keratinocytes (Fig 2c). Following mannan 
pretreatment of human keratinocytes for 60 min prior to 
incubation with Candida albicans, 6% of keratinocytes were 
FITC-positive, revealing a marked decrease in their Candida-
binding capacity (Fig 2d). 
Immunohistology of human skin sections The monoclonal 
antibody specific for human M M R (Lew et al, 1994) showed clear 
staining of individual cells in the dermis, whereas no positive cells 
were seen in the epidermis (Fig 3a). The polyclonal antibody raised 
against human MMR displayed a similar staining pattern in the 
dermis, but it also showed the staining of keratinocytes, which was 
more pronounced, affecting cells in the suprabasal layers (Fig 3b). 
With both controls, weak, diffuse, cytoplasmic staining was 
observed throughout the epidermis and dermis (not shown), 
indicating that the antibody staining was specific. These results 
suggest that the KcMR differs from the MMR. 
Isolation of KcMR To further characterize the KcMR, a 
human keratinocyte extract was subjected to mannose-Sepharose 
affinity chromatography. Gel electrophoresis of the eluted protein 
revealed a single band at ~200 kDa (Fig 4). The human MMR has 
a molecular weight of around 175 kDa. 
Western blotting On Western blots of human keratinocyte 
and HaCaT cell extracts, the polyclonal goat anti-human MMR 
antibody stained a band with a molecular weight of approximately 
200 kDa (Fig 5). 
125I-Man-BSA binding to freshly separated human keratino-
cytes Radioligand binding experiments were performed with 
I-Man-BSA (6X104 cpm per well) at 4°C to prevent 
internalization and degradation of the ligand. Competition studies 
revealed that unlabeled mannan dose-dependently inhibited 12:,I-
Man-BSA binding to freshly separated human keratinocytes, 
suggesting that 12T-Man-BSA binding to the cells was rnannan-
specific (Fig 6). 
Incubation of keratinocytes with increasing concentrations of 
12SI-Man-BSA resulted in increasing ligand binding to the cells 
(Fig 7). Analysis of the binding data via a nonlinear curve-fitting 
program (MxN-FIT) indicated a single class of mannose-binding 
sites with a KD of 1.4 X 10"8 M and a Blnax of 1 X 104 binding sites 
per cell. The Scatchard transformation of the data was linear, 
suggesting a single population of receptors (Fig 7, inset). 
Internalization of 125I-Man-BSA In separate experiments, 
keratinocytes were incubated with 4 X 10 cpm per well of 125I-
Man-BSA, with or without 3 mg per ml mannan, at 37°C for 10, 
20, or 30 min. The mannan-specific binding was calculated by 
subtracting the measured radioactivity in the presence of mannan 
(mannan-independent binding) from the radioactivity measured in 
the absence of mannan (total binding) (Fig 8). The mannan-
independent binding detected after a 10 min incubation at 37°C 
did not vary considerably on further incubation (20, 30 min), 
whereas the mannan-specific binding increased on longer 
incubation. After a 10 min incubation there was no difference in 
acid-labile and acid-stable specific radioactivity (Fig 9). After 30 
min incubation the considerable increase (8-fold) in mannan-
specific binding was acid-precipitable to almost 90%, whereas the 
acid-stable fraction exhibited only a slight change. This suggested 
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Candida cells in a final volume of 1 ml PBS and incubated for 120 min 
on a rotator at 37°C. The cells were then examined by fluorescence 
microscopy (Opton, Germany) and by flow cytometric analysis using a 
FACStar Plus Flow Cytometer (Becton Dickinson). Data were collected 
by using a linear amplifier for side scatter (SSC) and logarithmic 
amplifiers for forward scatter (FSC) and fluorescence intensity (FL1). 
FSC/SSC proved to be efficient in discriminating between human 
keratinocytes and Candida albicans cells, due to the substantial differences 
in structure and size. To determine the extent of adherence, non-
adherent yeasts were gated out and the green fluorescence of the 
keratinocytes was measured by using the FL1 channel. This allows a 
distinction of Candida-binding (FLl-positive) and non-binding FL1-
negative keratinocytes. Flow cytometric data (an average of 5 X 103 
events) were analyzed by the Cell Quest 3.1 F software (Becton 
Dickinson). To study the effect of mannan on the ability of keratinocytes 
to bind Candida cells, keratinocytes were incubated with 3 mg per ml 
mannan dissolved in PBS for 60 min before the adherence assay. 
Immunohis tology Skin biopsies were taken from disposed tissues of 
healthy individuals undergoing plastic surgery operations. The samples 
were embedded in cryomatrix (Shandon, Life Sciences International, 
U.K.), 7 flm sections were cut and fixed in acetone (10 min, 4°C), and 
the sections were stained with a monoclonal antibody (mAbis) against 
the human MMR (mouse IgGi) and with the goat antiserum against the 
purified human MMR (both kindly provided by Philip D. Stahl, 
Washington University, St. Louis, MO). 
The incubation step with the primary antibodies (1:50 dilutions) and 
the appropriate controls (mouse IgG], preimmune goat serum) for 60 
min at room temperature was followed with incubation of biotin-
conjugated secondary antibodies, and then streptavidin—biotin peroxidase, 
using the DAKO Strept ABC complex kit and its protocol (DAKO, 
Denmark). 3-Amino-9-ethylcarbazole (ABC, Sigma) was used as a 
peroxidase substrate. 2.5 ml AEC (4 mg AEC dissolved in 1 ml N,N-
dimethylformamide) was added to 17 ml 0.1 M acetate buffer (pH 5.2) 
and 10 |Al 30% H2O2- The sections were countetstained with hematox-
ylin. 
Isolation of KcMR Freshly separated human keratinocytes were 
collected from healthy individuals undergoing plastic surgery operations 
as described above. 2.4 X 10" keratinocytes were homogenized with a 
handheld Polytron homogenizer (Brinkmann Instruments, Westbury, 
NY) in loading buffer containing 0.5% Triton X-100, 10 mM Tris-HCl 
(pH 7.4), 1.25 M NaCl, 15 mM CaCl2, and 0.1 mM phenyl-
methylsulfonyl fluoride (PMSF) (all from Sigma). Debris was removed by 
centrifiigation (12,000#, 35 min). The receptor was bound to a mannose-
coupled epoxy-activated maimose-Sepharose 6B column (Pharmacia 
Biotech, Uppsala, Sweden) in loading buffer and subsequendy eluted 
with the same buffer containing 0.1 M mannose. The partially purified 
mannose-binding protein was subjected to electrophoresis in 7.5% 
polyacrylamide gel (PAGE) in sodium dodecyl sulfate (SDS) under non-
reducing conditions. Protein was visualized with silver staining 
(Sammons et al, 1981). 
Western blott ing Protein extracts from freshly separated human 
keratinocytes and the HaCaT human keratinocyte cell line (Boukamp 
ct al, 1988) were prepared in a lysis buffer of 1.5% SDS, 62.5 mM Tris-
HCl pH 6.8, 5 mM ethylenediamine tetraacetic acid, 5% 2-mercapto-
ethanol, 1 fig per ml PMSF, 1 fig per ml antipain, 1 fig per ml 
chymostatin, and 1 fig per ml leupeptin (all from Sigma). Lysates were 
centrifiiged and supematants were stored at -20°C. The extracted 
proteins of keratinocytes were separated by SDS-PAGE (with 9% 
separating gel) and then transferred to nitrocellulose membrane (Protran 
BA 83). Blots were blocked in Tris-buffered saline (150 inM NaCl, 25 
mM Tris-HCl pH 7.4) containing 0.05% Tween-20 and 3% non-fat dry 
milk (all from Sigma). Blots were incubated overnight at 4°C with a 
1:200 dilution of goat antiserum for the human MMR. Alkaline 
phosphatase conjugated mouse anti-goat immunoglobulin (Sigma) was 
used as secondary antibody at a 1:4500 dilution for 2 h at room 
temperature. Blots were developed by using 5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium substrate (Sigma). 
Radioligand binding study Man-BSA was trace-labeled with 125I by 
the chloramine T method (Salacinski et al, 1981). 5 X 10s keratinocytes 
were incubated with increasing concentrations of 125I-Man-BSA (0.25-5 
|ig per ml, 1 X 10s cprn per Mg) in DMEM containing 1% bovine 
serum albumin (BSA), 10 mM HEPES, and 1.2 mM CaCl2 in a final 
volume of 400 fll. The incubation lasted for 90 min at 4°C under 
continuous shaking, and was tenninated by washing the cells twice with 
ice-cold PBS. Cell-associated radioactivity was detected in a Packard 
gainma-spectrometer (Packard Instrument, Downers Grove, IL). 
Mannan-independent binding was determined in the presence of 3 mg 
per ml unlabeled mannan. The mannan-specific binding was defined as 
the difference between the total and the mannan-independent t z sI-Man-
BSA binding (Sato and Beuder, 1993). Each assay was carried out in 
duplicate in three separate experiments. For determination of the 
dissociation constant (An) and the number of binding sites per cell 
(Bnux). saturation curves were analyzed with the computerized nonlinear 
curve-fitting program MxN-FIT (Biirgisser, 1988). 
In competition studies the cells were incubated with 0.15 fig per ml 
125I-Man-BSA and with increasing concentrations of unlabeled ligand in 
the range 10-31X10 fig per ml. Competition studies were performed 
under the same conditions as the saturation assays. 
Internalization of 1 2 5I-Man-BSA Man-BSA was again trace-labeled 
with 125I by the chloramine T method. To determine the kinetics of 
internalization of lzsI-Man-BSA, a modified radioligand binding study 
was performed at 37°C (Ezekowitz et al, 1981). Briefly, keratinocytes (5 
X 10s per well) were incubated with 10 fig (10 X 10* cprn per fig) 
12SI-Man-BSA in the presence or absence of 3 mg per ml mannan in a 
final volume of 400 fll. After different time intervals (10, 20, and 30 
min), the binding was stopped by washing the cells four times with ice-
cold PBS, and the cell-bound radioactivity was measured with a gamma-
counter. The mannan-specific binding was defined as the total binding 
minus the mannan-independent binding. To examine how much of the 
cell-bound radioactivity was internalized, cells were treated for 3 min 
with acetic acid (pH 3) and then washed twice with ice-cold PBS. The 
acid-stable radioactivity represents internalized ligand, whereas the acid-
labile radioactivity is equivalent to surface-bound ligand (Arenberger et al, 
1993). 
Ca 2 + and trypsin effects To detennine the Ca2+ dependence of the 
Man-BSA binding sites, the radioligand binding study was performed in 
the presence of 10 mM ethylene glycol-bis(|i-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA) (Sigma) at 37°C. 
To investigate the trypsin sensitivity of the mannose-binding receptors, 
cells were incubated with 10 Mg P e r " J trypsin (type I from bovine 
pancreas, Sigma) for 10, 60, or 120 min prior to the binding assay. 
Flow cytometric detection of the KcMR 1 X 1 0 * freshly separated 
human keratinocytes were incubated with 100 fll goat anti-human 
MMR antiserum dissolved in 0.5% BSA-PBS at a dilution of 1:25 for 1 h 
on ice. For isotype control, non-immune goat setum was used. Cells 
were washed twice in PBS and incubated for another 1 h on ice with 
biotinylated mouse anti-goat IgG at 1:200 dilution. After washing again 
twice in PBS cells were incubated with 100 fll streptavidin-PE (Becton 
Dickinson, Heidelberg, Germany) at 1:100 dilution for 1 h on ice. The 
cells were then fixed in 1% paraformaldehyde and analyzed by flow 
cytometry using a FACStar Plus Flow Cytometer (Becton Dickinson). 
Data (an average of 10,000 events per sample) were analyzed with the 
Cell Quest 3.1 F program. 
Statistical analysis The paired Student's t test was used for statistical 
evaluation, a level p < 0.05 being taken as significant. The significance 
of the correlation between the Candida albicans cell counts and the 
colony forming units was detennined by analysis of variance. 
RESULTS 
Spontaneous and stimulated human keiatinocyte Candida 
albicans killing is inhibited by mannan and Man-BSA but not 
by Gal-BSA The spontaneous Candida killing activity of freshly 
separated keratinocytes was decreased by more than 50% by 
mannan at both 100 fig per ml and 500 fig per ml concentrations, 
indicating a potent inhibitory activity (Fig la). Pretreatment with 
a-MSH, IL-8, or UVB light induced a nearly 3-fold increase in the 
Candida killing activity of epidermal cells. Incubation with mannan 
resulted in a significant reduction in the percentage of all stimulated 
Candida. The mannan inhibition of the stimulated killing activity 
was higher at 500 fig per ml than at 100 fig per ml mannan 
concentration. The presence of 100 fig per ml or 500 fig per ml 
Man-BSA inhibited the spontaneous killing activity very similarly 
to mannan (Fig 16), but Man-BSA exhibited a higher inhibition 
than mannan at the corresponding concentrations of the activated 
killing. Our results are analogous to those obtained in experiments 
with macrophages (Marodi et al, 1994). The spontaneous Candida 
killing activity of freshly separated keratinocytes was not influenced 
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Table I. Comparison of keratinocyte mannose receptor 
(KcMR) with macrophage mannose receptor (MMR) 
KcMR M M R 
Number of sites per cell 1 X 104 2 X 10* 
KD(M) 1.8 X 10"8 10"8 
Internalization No t efficient Efficient 
Ca2+ dependency Dependent Dependent 
Sensitivity to proteolysis High High 
Recovery after proteolysis Rapid Rapid 
Molecular weight - 2 0 0 kDa - 1 7 5 kDa 
in the killing. Gal-BSA did not have any influence on the Candida 
killing activity of freshly separated human keratinocytes, suggesting 
that mannan and Man-BSA have specific inhibitory effects. 
Pretreatment of Candida cells with mannan did not protect the 
yeast from the fungicidal effect of the antimycotic drug ciclopirox 
olamine, ruling out the possibility that mannan and Man-BSA 
exerted a non-specific protective effect on Candida albicans cells, 
making them more resistant to killing. Similarly, mannan did not 
exert any influence on the Candida killing activity of human PMN 
leukocytes that lacked mannose receptor. These results confirm that 
mannan has a specific effect on the Candi'da-keratinocyte inter-
action. The adherence of Candida to keratinocytes was visualized 
by fluorescence microscopy and flow cytometric analysis. These 
data proved that freshly separated human keratinocytes bind 
fluorescein-labeled Candida albicans cells on their surface, and this 
can be inhibited by the addition of mannan. To characterize the 
mannose-binding sites on the surface of the keratinocytes, we 
performed radioligand binding assays with 12SI-Man-BSA at 4°C. 
Mannan exhibited a potent dose-dependent inhibitory effect on the 
12SI-Man-BSA binding of the keratinocytes. The binding assays 
indicated that the number of binding sites per keratinocyte is 
10.000 per cell with a K D of 1.4 X 10 -8 M. At 37°C, the trace-
labeled Man-BSA binding displayed a time-dependent increase and 
the binding was again inhibited by mannan. The majority (nearly 
90%) of the cell-bound 125I-Man-BSA was precipitable with acetic 
acid, indicating that most of the Man-BSA remained on the suiface 
of the keratinocytes and only a small portion was internalized. The 
depletion of Ca decreased the Man-BSA binding capacity of the 
keratinocytes. Proteolytic digestion with trypsin at 37°C consid-
erably reduced the binding activity, but removal of the surface 
receptors with trypsin was followed by a rapid recovery. 
Characteristic features of the mannose-binding structures of 
keratinocytes are compared with the characteristics of the MMR in 
Table I. These two structures exhibit similarities in the number of 
binding sites per cell, in the dissociation constants, in their 
sensitivity to proteolysis, and in their Ca2+-dependent activity. 
Macrophages internalize mannose efficiendy, but a similar 
phenomenon cannot be observed with keratinocytes. Whereas a 
monoclonal antibody against MMR did not stain keratinocytes, a 
goat anti-human MMR immune serum reacted with suprabasally 
localized keratinocyte membrane structures. Mannose-Sepharose 
chromatography of keratinocyte extracts isolated a single protein 
with an apparent molecular weight of ~200 kDa, and on Western 
blot, the goat anti-human MMR immune serum also recognized a 
band of around 200 kDa. The human MMR has a molecular 
weight around 175 kDa. These data indicate that the mannose-
binding receptors on human keratinocytes could be different from 
the human MMR. 
The ability of mannose binding is shared by a number of 
different Ca -dependent (type C) lectins (Weis et al, 1998). 
Whereas most of the members of the type C lectin group contain 
only a single carbohydrate-binding domain (Mullin et al, 1994), the 
known receptors have either 8 (MMR and phospholipase Ao 
receptor) or 10 (DEC 205 receptor) lectin domains, and it is likely 
that these domains cooperate with each other to enhance ligand 
avidity (Ezekowitz et al, 1991; Taylor et al, 1992). All three of these 
receptors appear to mediate various endocytotic phenomena 
(Harris et al, 1992; Jiang et al, 1995; Zvaritch et al, 1996). Our 
results indicate that the KcMR is probably not a member of the 
endocytotic type C lectins. Although our data clearly suggest that 
the KcMR plays a role in the Candida killing activity of the cells, in 
light of the differences between the MMR and the KcMR the 
mechanism of killing may be different. 
Our data indicate that the human KcMR is responsible for the 
initial phase of ma-Candida activity. Various effector mechanisms 
can restrict Candida growth in infected hosts. We have recendy 
demonstrated that nitric oxide (NO) plays a crucial role in the 
Candida killing mechanism of keratinocytes.2 The adherence of 
Candida cells to the KcMR could induce N O production. 
Numerous studies have reported that N O synthesis is a necessary 
component of non-specific defense mechanisms against various 
bacteria, viruses, and fungi (Liew and Cox, 1991). Human 
keratinocytes are sources of constitutive and inducible N O 
isoforms. It has been shown that IL-8, a-MSH, and UVB 
irradiation can induce N O production by keratinocytes (Bruch-
Gerharz et al, 1996; 1998). Several pathogens, such as Escherichia coli, 
Candida albicans, and Mycobacteria, have been shown to be sensitive 
to NO, and the chemical generation of N O on the skin surface may 
provide a protective mechanism against various pathogens (Fietro 
et al, 1996). N O synthesis could be mediated through MMR in 
chicken (Karaca et al, 1995). Mannose receptors may also be 
involved in the induction of human-beta-defensin-2 (hBD-2 
peptide antibiotic), which is highly effective against Candida 
albicans. Staphylococcus aureus, S. epldermidls, and Pseudomonas 
aeruginosa (Haider et al, 1997). It has been observed that the 
human skin contains a shield of endogenous peptide antibiotics 
(Gallo and Huttner, 1998). Besides the constitutively expressed 
antimicrobial peptides, a group of these proteins are inducible and 
can be recmited by contact with microorganisms. 
Our results reveal the presence and for the first time the 
physiologic importance in the host defense against Candida 
infection of mannose receptors on human keratinocytes. Further 
work is needed for a better characterization of their structure and 
function. 
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To the Editor: 
Candida albicans infections constitute an important medical problem, but the 
mechanisms of the host defense against Candida albicans cells have not been completely 
understood. We earlier reported that freshly separated human epidermal cells are capable 
of the phagocytosis and killing of Candida albicans [1]. This activity of epidermal cells 
appeared to be greatly enhanced after stimulation with a-melanocyte stimulating 
hormone (a-MSH), interleukin-8 (IL-8), or ultraviolet light in vitro [2-4]. Although 
inflammatory mediators are implicated in the Candida killing activity of epidermal cells, 
the exact mechanism is not known [5]. Since recently mannose receptors have been 
shown to be involved in the phagocytosis and killing of Candida albicans cells of 
monocytes and monocyte-derived macrophages [6, 7], we were interested in whether 
similar mechanisms exist in epidermal cells. 
The involvement of mannose receptors in the Candida albicans killing activity of 
epidermal cells was investigated by the inhibitory effect of mannan (an a-linked 
polymer of mannose) and mannose-bovine serum albumine (mannose-BSA, 23 mol 
mannose/mol BSA) on the killing activity. Mannan and mannose-BSA are the classical 
ligands of the mannose receptor, which substances were shown to inhibit Candida killing 
activity of macrophages by blocking specifically the mannose receptors [6]. Human 
epidermal cells were obtained from healthy individuals undergoing plastic surgery 
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earlier [8]. In several experiments cultured immortalized HaCat human keratinocyte cell 
line were used. In the Candida albicans killing assay, freshly separated human epidermal 
cells or HaCat cells were incubated with Candida albicans cells (dissolved in PBS 
containing 0.25% BSA) in a ratio of 1:2 for 90 min, with or without the presence of 0.1-1 
mg/ml mannan (Sigma, St. Louis, USA) or mannose-BSA (E/Y Labs, San Mateo, USA). 
Human cells were then lysed with 1% Triton X, and the percentage of dead Candida 
albicans cells was determined by staining with methylene blue. In several experiments, 
epidermal cells or HaCat cells were stimulated by 20 pg/ml of a-MSH (Sigma, St. Louis, 
U.S.A.) 1 h prior to the beginning of the killing assay. 
Table I 
The effect of mannan and mannose-BSA on the spontaneous and a-melanocyte stimulating hormone (a-MSH) 
induced Candida albicans killing activity of human epidermal cells (EC) in vitro 
Concentration of the principle Candida killing index 
unstimulated 
EC alone - 8.67±2.00 
EC + mannan 0.10 mg/ml 4.3710.58 
EC + mannan 0.50 mg/ml 4.6712.00 
EC + mannose-BSA 0.10 mg/ml 2.1710.71 
EC + mannose-BSA 0.50 mg/ml 3.1710.71 
a-MSH stimulated 
EC alone - 24.3312.08 
EC + mannan 0.10 mg/ml 12.0011.63 
EC + mannan 0.50 mg/ml 8.6713.61 
EC + mannose-BSA 0.10 mg/ml 5.6712.83 
EC + mannose-BSA 0.50 mg/ml .3.6711.41 
The Candida killing activity of EC is expressed as the percentage of non-viable, killed yeast cells counted 
under a light microscope after staining with methylene blue; data represent mean±SD of four independent 
experiments. Mannan and Mannose-BSA induced a significant decrease in the Candida killing index at 
each tested concentrations (p<0.05, Student t-test) 
Table I shows that both mannan and mannose-BSA dose-dependently inhibited the 
spontaneous Candida killing activity of freshly separated EC cells. Mannose-BSA proved 
to be more efficient in the inhibition of killing activity than mannan. a-MSH resulted in a 
2.5-fold increase in the Candida killing activity, and this increased killing activity could be 
completely inhibited by incubation of cells with mannan or mannose-BSA. Similar results 
were obtained using the HaCat human epidermal cell line (not shown). 
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The major components of the cell wall of Candida yeasts are mannan. Binding of 
mannan or mannose-BSA to specific mannose-receptors on the surface of macrophages 
inhibit Candida phagocytosis and killing, suggesting that attachment of the yeast cells to 
macrophages is essential for the killing [6]. In the present study we could show that 
probably similar mechanisms are implicated in the Candida albicans killing activity of EC, 
since mannan and mannose-BSA dose-dependently inhibited the Candida albicans killing 
activity of EC. This suggest that the interaction of the Candida cell wall-mannan with 
mannose-binding structures on the surface of the EC are essential in the killing activity. 
This mannose-binding structures are probably the mannose receptors, which have been 
well characterized on macrophages. The further characterization and regulation of 
mannose receptors on EC might be important in the understanding of the physiological 
role of the epidermis in the defense to mycotic infections. 
Acknowledgement. Supported by the grants of ETT T-01577/93 and OTKA F 013331. 
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Abstract 
Interleukin-8 (IL-8) plays a crucial role in the pathogenesis of inf lammatory and hyperproliferative diseases in various organs. 
The purpose of the present investigation was to establish whether there is any naturally occurring inhibitor of IL-8. Here we 
demonstrate that an IL-8 inhibitor (IL-8INH) is present in the supernatant of polymorphonuclear (PMN) leukocytes. The release 
of IL-8INH could be increased by stimulating the P M N leukocytes by concanavalin A. IL-8INH blocks the IL-8-induced 
chemotaxis and Candida albicans killing activity of P M N leukocytes and epidermal cells in vitro, and IL-8-induced neutrophil 
infiltration in the mouse ear in vivo. The mechanism of action of IL-8INH involves blocking of 125I-IL-8 binding to the IL-8 
receptor. Binding of 125I-IL-8 to neutrophils could not be displaced by the IL-8INH, however, preincubation of l 25I-IL-8 with 
IL-8INH increased binding inhibition, suggesting an interaction between IL-8 and the inhibitor. Crosslinking of 125I-IL-8 to 
IL-8INH shows that IL-8INH binds specifically to 125I-IL-8, and the IL-8INH protein has an apparent molecular weight of 52 
kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The partial purification of the IL-8INH on DEAE-Sephadex 
anion-exchange chromatography column also suggests a 5 0 - 6 0 - k D a inhibitor protein which blocks IL-8-induced effects on 
neutrophils by binding to IL-8. © 1998 Elsevier Science B.V. All rights reserved. 
Keywords: Cytokines; Interleukin-8; Leukocytes; Epidermal cells; Inhibition 
1. Introduction 
Interleukin-8 (IL-8) p lays an important role in the 
pathogenes i s o f acute and chronic inf lammatory dis-
eases, and might be involved in the invasion and metas-
tasis format ion o f certain mal ignant tumors [ 1 - 3 ] . IL-8 
is produced by a wide variety o f cell types, including 
monocytes , fibroblasts, endothel ial cells, keratinocytes 
and Langerhans cells in response to an inf lammatory 
st imulus [4]. A l t h o u g h IL-8 w a s initially characterized 
Abbreviations: EC, epidermal cell; IL-8INH, IL-8-inhibitor; PMN, 
polymorphonuclear. 
•Corresponding author. Tel.: + 3 6 62 455252; fax: +36 62 
455954; e-mail: kl@derma.szote.u-szeged.hu 
as a potent neutrophil chemotact ic and activating agent 
[5], it is a lso chemotact ic for T- lymphocyte s [6], 
basophi l s [7], and epidermal cells (EC) [8], Further-
more , IL-8 st imulates neutrophil degranulat ion and 
ox idat ive burst activity [9], evokes histamine release 
f r o m IL-3-primed basophi l s [10], inhibits IL-4- induced 
i m m m u n o g l o b u l i n E product ion in h u m a n B-cells [11], 
induces H L A - D R expression in kerat inocytes [12] and 
m o d u l a t e s neutrophil adhes ion to the endothe l ium [13]. 
W e demonstrated that the biological effects of IL-8 
cou ld be inhibited by pharmacologica l m o d u l a t i o n of 
the IL-8 receptor [14,15]. Since the biological effects o f 
cy tok ines m a y be m o d u l a t e d by soluble inhibitors, such 
as soluble receptors, receptor antagonis ts or carrier 
prote ins [16], we were interested in whether there is any 
0165-2478/98/$ - see front matter O 1998 Elsevier Science B.V. All rights reserved 
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naturally occurring inhibitor of IL-8. Here we report 
that the supernatant of polymorphonuclear (PMN) 
leukocytes contains an IL-8 inhibitor (IL-8INH), 
which suppresses both in vitro and in vivo activities 
of IL-8. 
2. Materials and methods 
2.1. Cytokines, reagents and media 
Human recombinant IL-8 and 125I-IL-8 were from 
Amersham, Germany. Phosphate-buffered saline 
(PBS), Dulbecco's modified Eagle's medium (DMEM), 
RPMI 1640, bovine serum albumin (BSA) and fetal 
calf serum (FCS) were obtained from Gibco (Eggen-
stein, Germany). Platelet activating factor (PAF), N-
formyl-Met-Leu-Phe (FMLP), the protease inhibitors 
aprotinin, benzamidine, N-p - tosyl - L - lysine chloro-
methyl ketone (TLCK), iodoacetamide and the 
crosslinking agent disuccinimidyl suberate (DSS) were 
obtained from Sigma (Munich, Germany). 
2.2. Isolation of PMN leukocytes and EC 
Human neutrophils were isolated from freshly 
drawn venous blood of healthy donors by dextran 
sedimentation and centrifugation over Ficoll-Hypaque 
(Pharmacia, Uppsala, Sweden), as previously de-
scribed [17]. Contaminating erythrocytes were lysed 
with hypotonic saline, and the PMN leukocytes were 
then washed with PBS and counted. EC were pre-
pared from the skin of healthy individuals undergoing 
plastic surgery as described earlier [8]. The skin slices 
were incubated overnight at 4°C in 0.5% trypsin solu-
tion (Boehringer, Mannheim, Germany). The cells re-
leased from the sheets were then passed through 
100-/<m nylon filters, pelleted, washed with PBS and 
counted. 
2.3. Preparation of PMN leukocyte supernatant 
containing IL-8INH activity 
Human neutrophils (2 x 108/ml) were incubated for 
30 min at 37°C in PBS, and then centrifuged (1500 x 
g for 10 min). In another experiment, 2 x 106/ml neu-
trophils were used for the generation of IL-8INH 
activity. Pooled cell supernatants from different 
healthy individuals were next centrifuged again 
(15000 x g for 30 min), and concentrated by ammo-
nium sulfate precipitation, followed by dialysis against 
PBS. The resultant supernatant, containing 100 pg/ml 
protein, referred to as IL-8INH, was tested for its 
ability to block the different activities of IL-8. PMN 
leukocyte supernatant was also obtained by incubat-
ing PMN leukocytes for 30 min at 37°C in PBS in the 
presence of different protease inhibitors, such as 50 
pg/ml of aprotinin, 5.0 mM benzamidine, 5.0 mM 
TLCK or 50 mM iodoacetamide. In a series of exper-
iments, PMN leukocyte supernatant was obtained by 
stimulating leukocytes for 30 min with 100 pg/ml 
concanavalin A (Con A) in RPMI 1640 medium. 
2.4. IL-8INH bioassays 
The chemotactic responses of PMN leukocytes and 
EC to IL-8 were studied by using a modified Boyden 
chamber technique. The upper part of the chamber 
contained 2 x 106 PMN leukocytes in RPMI 1640 or 
2 x 106 EC in DMEM, and the lower compartment 
contained 0.1-20 nM IL-8 preincubated for 60 min 
with PBS or concentrated IL-8INH at 4°C or 37°C. 
For PMN leukocyte chemotaxis, a 4-/im nitrocellulose 
filter (Sartorius) was used with a 90-min incubation 
time at 37°C. EC were incubated for 4 h at 37°C, 
using an 8-/im nitrocellulose filter. The filters were 
then removed and stained with hematoxylin-eosin, 
and the migrated cells were counted in three high-
power fields of a microscope. To investigate the spe-
cificity of IL-8INH, the effects of IL-8INH on 
10 " 8 - 1 0 " 1 2 M platelet activating factor (PAF), 
10-6—10—9 M FMLP or 50-300 //g/ml C5a induced 
PMN leukocyte chemotaxis were studied. 
In the C. albicans killing assay, 0.1-20 nM U n -
stimulated PMN leukocytes or EC were incubated 
with C. albicans cells (dissolved in PBS containing 
0.25% BSA) in a ratio of 1:2 for 90 min, with or 
without the presence of concentrated IL-8INH. Hu-
man cells were then lysed with 1% Triton X, and the 
percentage of dead C. albicans cells was determined 
by staining with methylene blue. 
2.5. Induction of PMN leukocyte accumulation in the 
mouse ear 
The central areas of both ears of mice were injected 
intradermally with 0.01 ml of 20 nM IL-8 preincu-
bated for 60 min with PBS or concentrated IL-8INH, 
or for controls with 0.01 ml PBS or IL-8INH alone 
coded by a randomized double-blind protocol. Each 
of the four treatment groups contained six animals. 
After 4 h, the animals were killed by cervical disloca-
tion, and each ear was removed, fixed in formalin and 
processed for routine histology by staining with 
hematoxylin-eosin. The histological sections of the 
mouse ear were scanned at x 100 magnification, and 
results were expressed as the average number of 
counted leukocytes present in each of three high-
power fields on each side of a central field containing 
the needle track. Statistical analysis was performed 
using Student's /-test. 
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Fig. 1. Demonstration of IL-8INH activity of PMN leukocyte supernatants in vitro. Inhibition of IL-8-induced Chemotaxis (A) and C. albicans 
killing activity (B) of PMN leukocytes and of EC (C,D) in vitro. The IL-8-induced Chemotaxis and C. albicans killing activity of PMN leukocytes 
and EC were measured in the presence ( • - • ) or absence ( • - • ) of IL-8INH, as described in Section 2. Values are means+ SD of the results 
of four independent experiments. 
2.6. i25I-IL-8 binding assay to PMN leukocytes 
The radioligand binding assay with 125I-IL-8 to PMN 
leukocytes was performed as described earlier [17]. 
Briefly, 2 x 106/ml PMN leukocytes in RPMI contain-
ing 1% BSA and 20 mM HEPES were incubated with 1 
nM 125I-IL-8 for 90 min at 0°C. The non-specific bind-
ing was determined by addition of a 100-fold excess of 
cold IL-8. In displacement studies, the IL-8INH was 
added after ligand binding. In other experiments, the 
125I-IL-8 was preincubated with IL-8INH for different 
time intervals before the ligand binding assays were 
performed. 
2.7. Crosslinking of 125I-IL-8 to IL-8INH 
To determine the molecular mass of IL-8INH, sam-
ples of P M N leukocyte supernatants containing IL-
8INH activity were incubated with 10 nM 125I-IL-8 for 
60 min at 4°C in the absence (lanes 2 - 4 ) or presence 
(lanes 5 - 7 ) of a 100-fold molar excess of unlabeled 
IL-8, without the crosslinker (lanes 2 and 5) or 
crosslinked with 2.5 mM DSS (lanes 3 and 6) or 5.0 
mM DSS (lanes 4 and 7) and subjected to SDS-PAGE 
and autoradiography. Lane 1 contained only 10 nM 
125I-IL-8. Each 125I-IL-8 sample contained 0.25% BSA, 
as provided by the manufacturer. 
2.8. Partial purification of IL-8INH 
Ammonium sulfate-precipitated PMN leukocyte su-
pernatant was chromatographed on a DEAE-Sephadex 
anion-exchange chromatography column (Pharmacia, 
Uppsala, Sweden), equilibrated in a 10 mM Tris-HCl 
buffer, pH 7.5, containing 1 mM EDTA and 1 mM 
mercaptoethanol. Bound fractions were eluated with 
equilibration buffers containing 50-300 mM NaCl. The 
eluated fractions were collected and tested on PMN 
leukocytes for IL-8INH activity by blocking 125I-IL-8 
binding to the cells. On the other hand, SDS-PAGE 
was performed parallely from fractions showing in-
hibitory activity. 
3. Results 
3.1. Inhibition of IL-8-induced Chemotaxis and C. 
albicans killing activity of PMN leukocytes and EC by 
IL-8INH 
The IL-8-induced Chemotaxis and C. albicans killing 
activity of PMN leukocytes were inhibited nearly com-
pletely by the IL-8INH obtained from the supernatant 
of PMN leukocytes (Fig. 1A,B). The IL-8-induced 
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Fig. 2. Inhibition of PMN leukocyte Chemotaxis by IL-8INH. The effects of different dilutions of IL-8INH on the 10 nM IL-8-induced Chemotaxis 
of PMN leukocytes were studied in vitro. Values are mean percentages of Chemotaxis inhibition + SD from three independent experiments. 
chemotaxis and C. albicans killing activity of EC, simi-
larly to those of neutrophils, were nearly totally 
blocked by the IL-8INH (Fig. 1C,D), suggesting that 
IL-8INH can modulate IL-8-induced effects on differ-
ent types of cells. There was no difference between the 
inhibitory potential of IL-8INH isolated at different 
neutrophil densities (2 x 106/ml or 2 x 108/ml; not 
shown). When IL-8INH was diluted to 1:500, there was 
still a significant decrease in the 10 nM IL-8-induced 
chemotaxis of PMN leukocytes (Fig. 2), indicating that 
IL-8INH has high potency in suppressing IL-8-induced 
effects on neutrophils. On the other hand, neutrophil 
chemotaxis induced by PAF, FMLP or C5a was not 
influenced by IL-8INH, suggesting that inhibition of 
the IL-8-induced chemotaxis of P M N leukocytes was 
rather a specific effect (not shown). 
3.2. Modulation of the inhibitory potential of IL-8INH 
When IL-8INH was prepared in the presence of the 
protease inhibitors aprotinin, benzamidine, TLCK or 
iodoacetamide, there was no change in the potency of 
IL-8INH to suppress the IL-8-induced chemotaxis of 
neutrophils (Table 1). This suggests that IL-8INH is 
probably not formed by proteolytic cleavage (shedding) 
of the membrane IL-8 receptor. However, when IL-
8INH was isolated from Con A stimulated neutrophil 
supernatants, the IL-8-induced neutrophil chemotaxis 
dropped by 60%, suggesting that Con A stimulated the 
IL-8INH release from neutrophils (Table 1). 
3.3. Inhibition of IL-8-induced PMN leukocyte 
infiltration of mouse ear by IL-8INH 
Injection of 20 nM IL-8 into the mouse ear induced 
a significant accumulation of PMN leukocytes but not 
of monocytes and lymphocytes in the oedematous con-
nective tissue at the site of injection (Fig. 3), shows only 
the number of infiltrating neutrophils in the different 
treatment groups. When IL-8 was preincubated for 60 
min with the concentrated IL-8INH, there was signifi-
cantly less pronounced neutrophil infiltration in the 
mouse ear as compared to the IL-8 injected animals, 
suggesting that IL-8INH had a profound inhibitory 
effect on the IL-8-induced neutrophil infiltration. PBS 
and IL-8INH alone induced only slight oedema without 
Table 1 
Modulation of the inhibitory potential of IL-8INH 
In presence of Chemotactic index 
PBS 37.3 + 4.5 
+ Aprotinin (50.0 /tg/ml) 33.6 ±4 .4 
+ Benzamidine (5.0 mM) 38.5 ±5 .4 
+ TLCK (5.0 mM) 36.2 ± 4.8 
+ Iodoacetamide (50.0 mM) 35.8 ±5 .5 
RPMI 1640 38.1 +4 .7 
+ Con A (100 /rg/ml) 15.2 ± +3.3 
IL-8INH was prepared in PBS or RPMI in the presence of different 
protease inhibitors or Con A, and the effects on the 10 nM IL-8-in-
duced chemotaxis of neutrophils were studied. Values are means ± 
SD of the results of three independent experiments. 
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Fig. 3. Effect of IL-8INH on IL-8-induced PMN leukocyte accumula-
tion in mouse ear. Groups of mice were treated intradermally at the 
centre of each ear with 0.01 ml of 20 nM IL-8 preincubated for 60 
min with PBS or concentrated IL-8INH, or with 0.01 ml PBS or 
IL-8INH alone (six animals per group). Hematoxylin-eosin stained 
histological sections were scanned at x 100 magnification. The data 
are expressed as means + SE of counted PMN leukocytes per three 
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Fig. 4. Inhibition of 125I-IL-8 binding to PMN leukocytes by IL-
8INH. Radioligand binding assay was performed by incubating PMN 
leukocytes with 1 nM l25I-IL-8 in RPMI containing 1% BSA and 20 
mM HEPES for 90 min at 0°C. The non-specific binding was 
determined by the addition of a 100-fold excess of cold IL-8. To 
determine whether IL-8INH can modulate l25I-IL-8 binding to 
PMNL, 12SI-IL-8 was preincubated with IL-8INH for different time 
intervals at 37°C before the ligand binding assay. Values are means + 
SD of three separate experiments. 
causing significant leukocyte infiltration. These results 
suggest that IL-8INH also functions in vivo, suppress-
ing IL-8-induced PMN leukocyte accumulation in the 
mouse ear. 
3.4. Inhibition of 125I-IL-8 binding to PMN leukocytes 
by IL-8INH 
To determine how the PMN leukocyte-derived in-
hibitor blocks the actions of IL-8, we investigated l25I-
IL-8-binding to PMN leukocytes in the presence of 
IL-8INH. When 125I-IL-8 was preincubated with IL-
8INH at 37°C for different time intervals before the 
125I-IL-8 binding assay to PMN leukocytes, the IL-
8INH exerted a pronounced inhibition of IL-8-binding 
to neutrophils. The inhibition of specific 125I-IL-8 
binding reached its maximum after preincubation for 
30 -60 min (Fig. 4). Similar results were obtained 
when the IL-8INH was preincubated with IL-8 at 4°C, 
suggesting that the inhibition was not due to enzy-
matic degradation of IL-8. When IL-8INH was added 
after the ligand binding assay, IL-8INH did not disso-
ciate 125I-IL-8 from its receptor (not shown). 
3.5. Crosslinking of ,25I-IL-8 to IL-8INH 
To determine the molecular mass of IL-8INH, sam-
ples of PMN leukocyte supernatants were incubated 
with 125I-IL-8 in the presence or absence of an excess 
of unlabeled IL-8, crosslinked with DSS and subjected 
to SDS-PAGE under reducing conditions, followed by 
autoradiography. Such experiments showed that, in 
addition to the 8-kDa band of 125I-IL-8, there are two 
other bands, of approximately 80 and 60 kDa (Fig. 5). 
The 80-kDa band corresponds to 125I-IL-8 non-specifi-
cally bound to a serum protein, since unlabeled IL-8 
(lanes 5 - 7 ) did not inhibit this binding. This protein is 
HSA since it reacted with anti-human serum albumin 
in a Western blot reaction (not shown). On the other 
hand, addition of an excess of unlabeled IL-8 (lanes 
5 - 7 ) inhibited detection of the 60-kDa band in lanes 
3 - 4 , where DSS was added to crosslink the I25I-IL-8 
with the putative IL-8INH protein. This experiment 
indicates that IL-8INH has a mass of % 52 kDa (after 
subtraction of the 8 kDa corresponding to IL-8). 
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Fig. 5. Crosslinking of ,25I-IL-8 to IL-8INH. Samples of PMN 
leukocyte supernatants were incubated with 10 nM 125I-IL-8 for 60 
min at 37°C in the absence (lanes 2-4) or presence (lanes 5-7) of a 
100-fold molar excess of unlabeled IL-8, without the crosslinker 
(lanes 2 and 5) or crosslinked with 2.5 mM DSS (lanes 3 and 6) or 5.0 
mM DSS (lanes 4 and 7) and subjected to SDS-PAGE and autoradio-
graphy. Lane 1 contained only 10 nM l25I-IL-8. 
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Fig. 6. Partial purification of IL-8INH. PMN leukocyte supernatant 
was chromatographed on a DEAE-Sephadex anion-exchange chro-
matography column, and bound fractions were eluated with 50 mM 
NaCl (fractions 1-4), 100 mM NaCl (fractions 5-8), 150 mM NaCl 
(fractions 9-12), 200 mM NaCl (fractions 13-15) and 300 mM NaCl 
(fractions 16-19). Column fractions were tested on the 125I-IL-8 
binding to neutrophils, and values represent percent inhibition of 
binding (%). Upper panel shows SDS-PAGE running under reducing 
conditions from fractions 8-15. 
3.6. Partial purification of IL-8INH 
When PMN leukocyte supernatant was chro-
matographed on a DEAE-Sephadex anion-exchange 
chromatography column, and bound fractions were 
eluated with 50-300 mM NaCl, the highest inhibitory 
effect on 125I-IL-8 binding was observed in fraction 
numbers 9 -12 , which were eluated by 150 mM NaCl 
(Fig. 6). SDS-PAGE of these fractions showed in addi-
tion to the band of a 67-kDa protein (which is probably 
the human serum albumin) 50-60-kDa protein. Since 
the fractions of 13-15 also contained the 67-kDa 
protein without having any inhibition of 125I-IL-8 bind-
ing to neutrophils, this suggests that the protein respon-
sible for the inhibitory effect should be the 50-60-kDa 
protein. 
trophils could be increased by stimulating the cells by 
Con A. We have shown that IL-8INH binds specifically 
to IL-8, and that the inhibitory effect of IL-8INH is 
mediated by blocking ligand binding to the effector 
cells. 
Many cytokine inhibitors exert their action by bind-
ing to the free cytokine in solution, precluding its 
binding to specific membrane receptors. Soluble recep-
tors that lack transmembrane and intracytoplasmic do-
mains, but retain the ligand-binding extracellular 
portion, and non-receptor cytokine inhibitors are the 
two main types of cytokine-binding inhibitors [16]. The 
soluble receptors may arise from proteolytic cleavage of 
the original membrane-bound receptor, or by synthesis 
from separate, alternatively spliced mRNAs coding for 
soluble forms. The IL-8INH described here is probably 
not the truncated form of the IL-8 receptor derived by 
proteolysis, since protease inhibitors did not influence 
the IL-8INH activity of the PMN leukocyte superna-
tant. Since the IL-8 receptor belongs in the chemokine 
receptor family with seven transmembrane domains 
[18,19], an alternative splicing of the receptor is also 
unlikely. Additionally, the IL-8INH activity of the 
PMN leukocyte supernatant could not be absorbed out 
with antibodies against the IL-8 receptor (not shown), 
suggesting that the IL-8INH protein is not a fragment 
of the IL-8 receptor. Besides soluble receptors, serum 
and urinary proteins (unrelated to cellular receptors) 
have been reported to be able to bind certain cytokines 
and in some cases to inhibit their activity [16]. IL-8INH 
may be such a cytokine-binding protein, which, by 
interacting with IL-8, prevents ligand binding to the 
effector cells, causing loss of the biological activity of 
IL-8. To our knowledge, no naturally occurring in-
hibitory factor directed against IL-8 activity has been 
reported yet. Since IL-8 exerts potent proinflammatory 
activities, the further biochemical characterization of 
IL-8INH might be of therapeutic potential. 
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4. Discussion 
We have demonstrated that the supernatant of PMN 
leukocytes contains a protein of approximately 52 kDa, 
which suppresses the IL-8-induced chemotaxis and C. 
albicans killing activity of PMN leukocytes and EC in 
vitro. This protein inhibited IL-8-induced neutrophil 
infiltration into the mouse ear, suggesting that it also 
functions in vivo. The release of IL-8INH from neu-
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Abstract 
Changes in the microflora on oral carcinoma surfaces may lead to both local and systemic infections, which may complicate the 
morbidity of the patient suffering from oral malignant neoplasms. Thus, anticancer therapy, irradiation, chemotherapy or surgery 
impairs the defence mechanism of the oral mucosa and is accompanied by proliferation of the mucosal biofilm with overgrowth of 
yeast and bacteria. This study investigates the inhibition of the biofilm present on the surface of oral squamous cell carcinomas. 
Biofilm samples were obtained from the central surface (1 cm2) of each lesion in 10 patients (eight male, two female; mean age: 47.6 
years; SD ± 7.6) before any antibiotherapy or tumour treatment. Patients were randomly divided into two groups and were rinsed 
with Meridol mouthrinse (amine fluoride) or placebo (saline solution) for 7 days. Samples were repeatedly taken from the same site 
after rinsing. Samples were transported in pre-reduced brain heart infusion broth and cultured within 1 h of removal, using aerobic 
and anaerobic complete and selective media. Total aerobic and anaerobic counts were determined and isolated bacteria were iden-
tified. The median counts of colony forming units (CFU/ml) after rinsing with Meridol were significantly lower for both aerobes 
and anaerobes than before rinsing with Meridol. (For aerobes before rinsing: 1.35 x 106, after rinsing: 7.55 x 10s; p = 0.025; for 
anaerobes before rinsing: 1.39 x 106, after rinsing: 7.15 x 10s; p = 0.011. Rinsing with placebo: no significant difference was found. 
Aerobe median counts before rinsing: 1.17 x 106, after rinsing: 1.03 x 10s, and for anaerobes: before rinsing 1.75 x 106, after rin-
sing: 1.51 x 106;/> > 0.05 [Wilcoxon test].) It was concluded that 7-days (three times a day) Meridol rinsing significantly reduced the 
surface biofilm of oral carcinoma compared to rinsing with placebo. Clinical examination indicated no irritation ct£ the mucosa. The 
mouthrinse was well tolerated by the patients, who commented on a reduction in burning sensation and bad. breath. Besides routine 
oral hygiene, rinsing itself could reduce patient morbidity. The findings of the present study indicate that in addition to any other 
oral focus, the lesion itself, when ulcerated, should receive direct antimicrobial treatment so as to reduce patient morbidity and 
enhance quality of life. £ 2000 Elsevier Science Ltd. All rights reserved. 
Keywords: Oral cancer; Biofilm: Focal infection: Morbidity: Infection control 
1. Introduction 
Changes in the microflora on oral mucosa after can-
cerous alteration may lead to both local and systemic 
infections, which may complicate the morbidity of the 
patient suffering from oral malignant neoplasm. Anti-
cancer therapy, irradiation, chemotherapy or surgery 
further impairs the defence mechanism of the oral 
mucosa with resultant proliferation of the mucosal bio-
* Corresponding author. Tel.: + 36-62-455-299; fax: + 36-62-455-
282. 
E-mail address: nagykatalin@imail.tiszanet.hu (K. Nagy) 
film with overgrowth especially of yeast and anaerobic 
bacteria [1], 
The oral cavity harbours hundreds of different 
microbial species. This complex microflora shows great 
quantitative and qualitative variation at different loca-
tions within the oral cavity. In health, however, these 
attain a characteristic microflora that is homeostatic 
and characteristic for each oral site. The nature and 
type of microflora is dependent on many factors 
including the pH, Eh, and nutrient availability at the site 
[2]. Mucosal infections can be caused by potentially 
pathogenic micro-organisms of extraoral origin or by a 
shift within the normal commensal microflora. Oral 
1368-8375/00/$ - see front matter © 2000 Elsevier Science Ltd. All rights reserved. 
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mucosal lesions, in addition, often develop an opportu-
nistic microflora in immunocompromised patients and 
manifest in various ways. Once the integrity of the epi-
thelial barrier is compromised, the underlying tissues 
are exposed to the large and varied population of micro-
organisms resident in the oral cavity. Bacteria, yeast or 
viruses may appear as the primary cause of mucosal 
lesions or as secondary invaders in an already estab-
lished non-infectious mucosal lesion. The compromised 
host, either systemically or locally, may suffer a dis-
turbed ecological balance [3]. Focal infection of oral 
origin may derive from closed or open sites. From the 
oral foci, micro-organisms or their products may gain 
entry to deeper tissues directly by spreading along fas-
cial planes, or even along blood or lymph vessels or 
nerves [4], Anticancer therapy, such as radiation and/or 
chemotherapy may result in epithelial atrophy and 
ulceration and in granulocytopenia and reduced salivary 
secretion. These changes result in tissue with reduced 
barrier function and impaired ability to heal and resist 
entry of coating organisms or pathogens, thus increas-
ing the risk of systemic infections [5]. While oral hygiene 
and anticancer-treatment effects have been considered 
[6-9], little attention appears to have been directed to 
the microflora of the lesion itself, or to the relevance of 
that microflora to overall patient morbidity. We have 
previously compared the biofllm of the tumour sur-
face and of the adjacent healthy mucosa of the same 
patient and shown significantly higher colony counts of 
both aerobic and anaerobic bacteria at the tumour sites 
[10], The purpose of this study was to evaluate the effect 
of mouth-rinsing with a widely used amine fluoride 
preparation (Meridol"1 three times a day) on the biofllm 
present on the surface of oral squamous cell carcino-
mas. There is some evidence that supports a local role 
for alcohol in the aetiology of oral cancer coming from 
studies on mouthrinse users. Although the use of mouth-
rinse containing alcohol may not represent a significant 
risk factor for oral cancer among non-tobacco users and 
non-drinkers [11], there is an elevated risk for tobacco 
users who do not drink [12], This evidence was ex-
tremely important for us in making the decision of 
exclusively using the non alcoholic version of Meridol 
mouthrinse. 
2. Materials and methods 
Ten patients (eight male, two female; mean age: 47.6 
years) were enrolled in the study. All gave their volun-
tary written consent to take part in the study. Patient 
selection was carried out according to the tumour clas-
sification described by Langdon et al. [13]. All lesions 
1 Meridol" mouthwash—(non-alcoholic version) amine fluoride/ 
stannous flouride, GABA International AG, Switzerland. 
were ulcerated keratinising squamous cell carcinoma 
localised to the sublingual region except one which 
was localised to the mandibular alveolar process. None 
of the patients had received antibiotic, immunosuppres-
sive, irradiation or chemotherapy during the preceding 
6 months. Concerning etiological data, eight patients 
were heavy drinkers (drank in excess of 6 units/day) and 
smoked more than 10 cigarettes daily. Two patients' 
alcohol intake was moderate (drank 2-5 units/day) and 
one of these had never smoked, while the other subject 
had stopped smoking 3 years prior to the study [14], The 
first five patients (Group M) rinsed with Meridol solu-
tion three times a day. The other five patients (Group 
PI) rinsed with placebo (flavoured saline solution), both 
for 7 days. Preparations were in identical containers 
with a random code numbering and the study was on a 
double blind basis (Table 1). 
Biofllm samples were obtained with sterile cotton 
swabs from the centre of a 1-cm2 tumour lesion surface. 
Samples were taken from the same site after 7 days rin-
sing either with Meridol solution (Group M) or with 
placebo (Group PI). Special, non-alcoholic Meridol 
solution was prepared for the study, given well-known 
cancer-related effects of alcohol on oral mucosa [6]. 
Clinical examinations were carried out and interviews 
were sought concerning mucosal burning sensation, 
sensitivity, halitosis before and after rinsing carried out 
by the same health care professional. Patients were not 
instructed to perform any special oral hygiene prior to 
or during the rinsing period. 
Samples were removed with the swabs and trans-
ported in 1-ml pre-reduced brain heart infusion (BHI) 
broth to the microbiology laboratory immediately after 
collection. All cultures were commenced within 1 h of 
sampling. After gentle dispersion (Branson 1210 Ultra-
sonic B.V., Soest, Netherlands), the suspensions were 
diluted (lO-'-lO - 6) in pre-reduced BHI broth and 100 
pi of each dilution and 100 pi of the corresponding 
undiluted suspension were plated immediately on selec-
tive and non-selective media. Columbia agar base 
(Oxoid, UK) supplemented with 5% (v/v) cattle blood 
haemin and vitamin K1 was used to enumerate the total 
cultivable bacterial flora. Veillonella spp. were isolated 
from Veillonella agar (Difco). Rogosa agar (Difco, 
Detroit, MN) was used for the selective isolation of 
lactobacilli and cadmium-fluoride containing medium 
of identification of Actinomyces (CFAT) agar (Difco) 
for Actinomyces spp. and for calculation of the total 
aerobic bacterial flora, heat-treated Columbia agar 
supplemented with 5% (v/v) cattle blood (chocolate 
agar) was used. For the selective growth of streptococci 
and Enterobacteriaceae, Mitis Salivarius Agar (Difco) 
and Endo agar (Difco), respectively, were applied. 
Yeasts were selectively cultured on Sabouraud Dextrose 
agar (Difco). For aerobic bacteria, the plates were cul-
tured at 37°C in a 5% C02-containing environment 
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Table 1 
Tumour classification and etiological factors for study group of patients with oral carcinoma11 
Patient No. Age (years) Gender Smoking Alcohol Tumour classification 
S T N M P 
Group Meridol 
1 48 m + + + s6 T2 N1 M0 P3b 
2 52 m + + + S6 T2 N1 M0 P3c 
3 43 m + + S6 T3 N3 Ml P3d 
4 38 m + + + S7 T2 N3 M0 P3c 
5 56 m + + + S6 T2 N1 M0 P3b 
Group Placebo 
6 60 m + + + S6 T3 N2 M0 P3c 
7 41 m + + + s* T1 N1 M0 P3b 
8 50 m + + + S6 T2 N2 M0 P3b 
9 49 fm + + + S6 T2 N1 M0 P3b 
10 39 fm - + + S6 T1 NO M0 P3b 
11 + , Moderate drinker (2-5 units/day); + + heavy drinker (more than 6 units/day). 1 unit of alcohol equals 0.03 1 (1 oz) of whiskey, 0.12 1 of 
wine or 0.24 1 of beer. - , no smoking admitted. 
(New Brunswick Scientific, Edison, NJ, USA) for 48 h. 
For the isolation of anaerobes, cultures were performed 
in an anaerobic chamber (Bactron, Sheldon Man, Ore-
gon, USA) for 6 days at 37°C. The selective agar media 
for the isolation of Enterobacteriaceae were incubated at 
37°C for 24 h. Yeast was isolated on medium cultivated 
at 37°C for 24 h and at room temperature for a further 5 
days. After incubation, total aerobic and anaerobic col-
ony counts were determined. Isolated bacteria were 
identified by ATB (Automated identification system. 
Biomerieux, Lyon, France) identification procedures. 
3. Results 
The median number of colony forming units (CFU/ 
ml) before and after rinsing with Meridol or placebo 
were compared using Wilcoxon test (Fig. 1). For Group 
UDGCFLTnl 






Before rinsing with IVferidd Mer rinsing with li/bridd Before rinsing with Racebo Mer rinsing with Raoeto 
Fig. 1. Median total aerobic and anaerobic counts before and after rinsing with Meridol and Placebo. CFU, colony forming unit. 
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M the bacterial counts were significantly lower for 
both aerobes and anaerobes after rinsing. (Aerobe 
median count before rinsing: 1.35 x 106, after rinsing: 
7.55 x 105; p = 0.025; anaerobe median count before 
rinsing: 1.39 x 106, after rinsing: 7.15 x 10s; p = 0.011.) 
For Group PI, no significant difference was found. 
(Aerobe median count before rinsing: 1.17 x 106, after 
rinsing: 1.03 x 106; p > 0.05; anaerobe median count 
before rinsing: 1.75 xlO6 , after rinsing: 1.51 x 106; 
p > 0.05.) 
Concerning the organisms found at the tumour site 
before and after rinsing (Tables 2 and 3) with Meridol, 
Table 2 
Isolation frequency of aerobic species at the tumour site before 
and after rinsing 
Spccies Before rinsing After rinsing 
Meridol Placebo Meridol Placebo 
Gram-positive 
Streptococcus mitis 5 5 2 4 
Streptococci a-haemolytic 5 5 4 4 
Streptococcus salivarius 3 2 3 1 
Streptococcus sanguis 3 2 4 2 
Streptococcus epidermidis 4 3 4 2 
Staphylococcus aureus 5 2 1 2 
Enterococcus faecalis 5 1 2 0 
Gram-negative 
Haemophilus influenzae 4 0 0 0 
Neisseria spp. 3 1 1 1 
Branlmmella catarrlialis 2 0 1 0 
Serratia spp. 1 2 0 1 
Escherichia coli 1 1 1 0 
Pseudomonas spp. 2 1 3 2 
Capnocylopliaga spp. 1 0 1 0 
Actinobacillus 5 4 2 4 
actinomylecemcomitans 
Campylobacter 4 1 1 3 
Candida albicans 5 5 1 4 
Table 3 
Isolation frequency of anaerobic species at the tumour site before 
and after rinsing 
Species Before rinsing After rinsing 
Meridol Placebo Meridol Placebo 
Gram-positive 
Peptostreptococcus spp. 1 3 1 3 
Lactobacillus spp. 5 4 3 5 
Propionibacterium spp. 2 1 0 1 
Clostridium spp. 1 0 0 0 
Gram-negative 
Prevotella spp. 2 3 0 3 
Veillonella spp. 5 5 5 5 
Treponema 1 0 0 0 
Fusobacterium 4 3 2 3 
Spirochaetes 1 1 0 1 
Porphyromonas 2 1 2 2 
Streptococcus mitis, Staphylococcus aureus and Entero-
coccus faecalis were isolated from at least twice as many 
tumour surfaces before the rinsing. Of the aerobic 
Gram-negative species isolated, Haemophilus influenzae, 
Neisseria spp., and Serratia spp. were found more fre-
quently before rinsing than after. Also, Campylobacter, 
Actinobacillus actinomycetemcomitans and Capnocyto-
phaga were found more frequently and Porphyromonas 
at the same frequency before Meridol rinsing. Anaero-
bic Gram-negative bacteria were also found more 
frequently before rinsing, except Veillonella spp. Spiro-
chetes, Fusobacterium, Treponema and Prevotella were 
isolated only before rinsing from the tumour surface. Of 
the Gram-positive anaerobes Clostridium was the only 
species isolated exclusively before rinsing from the 
tumour surface. Candida albicans were isolated in every 
sample before rinsing, but only in two patients after 
rinsing. 
Rinsing with placebo solution resulted in an increase 
in the numbers of anaerobe species isolated. There was 
no real difference in aerobes. It was concluded that 
7-days (three times a day) Meridol rinsing significantly 
reduced the surface biofilm of oral carcinoma, notably 
of Candida and oral anaerobes. Clinical examination 
indicated no irritation of the mucosa that are frequently 
associated with systemic infection in immunosuppres-
sed patients. The mouthrinse was well tolerated by the 
patients, who commented on a reduction in burning 
sensation and bad breath and increasing comfort by 
using the mouthwash. Placebo group has tolerated the 
mouthrinse well, but none of the group members has 
commented on a reduction of burning sensation. 
4. Discussion 
The present study has shown that the cancer lesion 
itself may greatly increase the local and systemic infec-
tion risk to oral cancer patients, even before specific 
tumour treatment. It is critical that an appropriate oral 
hygiene regimen be applied as soon as a definitive diag-
nosis has been made and the decision is made before 
radiation or chemotherapy. Furthermore, most head 
and neck operations are. associated with bacterial con-
tamination of the operative field by flora of the oral 
cavity and the risk for subsequent wound infection is 
substantial [15]. Local infection is often painful and 
affects the well-being of the patient. Systemic infection 
can lead to metastatic abscess formation and other 
effects that can be life threatening in the case of patients 
immunosuppressed by the cancer or the treatment 
[1,16]. Infection control by oral hygiene programmes, 
including topically applied agents, is highly recom-
mended for such patients [17,18]. 
Besides routine oral hygiene, rinsing itself could 
reduce patient morbidity [19-21] either by mechanical 
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cleansing of the mucosa, or antimicrobial effect of the 
mouthrinse. The findings of the present study indicate 
that, in addition to any other oral focus, the lesion itself 
when ulcerated should receive direct antimicrobial 
treatment so as to reduce patient morbidity and enhance 
quality of life. The amine fluoride preparation evalu-
ated, given its proven activities and anti-plaque efficacy, 
its safety record and the results reported here, would 
seem an appropriate adjunct to oral hygiene pre- and 
post-therapy for oral cancer patients. Results of this 
study suggests that certain decontamination of oral 
cavity can be achieved by topical antimicrobial treat-
ment, especially concerning Gram-negative anaerobes 
and Candida albicans. Further clinical trials and more 
extensive quantitative and qualitative bacteriologic stu-
dies are needed to conclude the efficacy of the antibiotic 
mouthwash in the reduction of wound infection, or 
mucositis caused by chemotherapy or irradiation. 
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ÖSSZEFOGLALÁS 
Az interleukin-8 (IL-8) fontos szerepet játszik gyulladásos 
és hiperproliferatív betegségek patogenezisében. A szer-
zők azt vizsgálták, hogy létezik-e természetes IL-8-inhibi-
tor. Eredményeik szerint polimorfonukleáris (PMN) leuko-
citák felülúszója egy az IL-8 hatását gátló inhibitort 
(IL-8INH) tartalmaz. Az IL-8INH gátolja a PMN leukoci-
ták IL-8 által kiváltott kemotaxisát és Candida albicans 
killing aktivitását in vitro, valamint az egérf&lbe oltott IL-
8 neutrofil infiltrációt kiváltó hatását in vivo. Az IL-8INH 
gátolja a mI-IL-8 kötését az IL-8 receptorhoz. Keresztkö-
tési vizsgálattal igazolták, hogy az IL-8INH egy 52 kDa 
molekulasúlyú fehérje. 
Kulcsszavak: 
interleukin-8 - interleukin-8 inhibitor -
kemotaxis 
Az interleukin-8 (IL-8) fontos szerepet játszik akut és kró-
nikus gyulladásos betegségek patogenezisében, de bizo-
nyos tumorok inváziós és metasztatizálő képességét is be-
folyásolja (2, 6, 8). Az IL-8 stimulációt követően számos 
sejtben termelődik (13), kemotaktikus hatású neutrofil 
leukociták (16), T-limfociták (11), bazofilek (12) és kera-
tinociták (14) számára, a granulociták degranulációját és 
az oxidatív folyamatokat aktiválja (18), IL-3 által aktivált 
bazofilekből hisztamin felszabadulást vált ki (3), a neutro-
filek felszínén a Mac-1 (CDllb/CD18) adhéziós moleku-
la expresszióját eredményezi (4), HLA-DR expressziét 
vált ki keratinocitán (9), ugyanakkor gátolja az IgE terme-
lést 810). Munkacsoportunk korábban kimutatta, hogy az 
* Dr. Dobozy Attila egyetemi tanár 60. születésnapja tiszteletére 
SUMMARY 
Interleukin-8 (IL-8) plays a crucial role in the pathogene-
sis of inflammatory and hyperproliferative diseases. It 
was investigated whether there is any naturally occurring 
inhibitor of IL-8. The authors demonstrate that an IL-8-
inhibitor (IL-81NH) is present in the supernatant of poly-
morphonuclear (PMN) leukocytes. IL-8INH blocks the IL-
8-induced chemotaxis and Candida albicans killing of 
PMN leukocytes in vitro, and IL-8-induced neutrophil in-
filtration in the mouse ear in vivo. The mechanism of acti-
on ofIL-8INH involves blocking qfmI-IL-8 binding to the 
IL-8 receptor. Crosslinking of ,2>I-IL-8 to IL-8INH shows 
that IL-8INH binds specifically to mI-IL-8, and the IL-
8INH protein has an apparent molecular weight of a 52 
kDa. 
Key words: 
interleukin-8 - interleukin-8 inhibitor -
chemotaxis 
IL-8 biológiai hatásai gátolhatők az IL-8 receptor farma-
kológiai modulálásával (7, 17). Mivel a citokinek bioló-
giai hatásai szolubilis inhibitorokkal, úgymint szolubilis 
receptorokkal, receptor antagonistákkal vagy hordozófe-
héijékkel gátolhatók (5), célul tűztük ki annak vizsgálatát, 
hogy létezik-e természetes IL-8 inhibitor. 
Módszerek 
Anyagok 
Humán rekombináns IL-8 és ,aI-IL-8 az Amersham (Németország), 
foszfát puffer (PBS), Dulbecco modifikált Eagle médium (DMEM), 
RPMI 1640, bovin szérum albumin (MBSA) és fötális borjúszérum 
(FCS) a Gibco (Németország), a trombocita aktiváló faktor (PAF), 
N-formyl-Met-Leu-Phe (FMLP), a proteáz inhibitor aprotinin, ben-
zamidine, N-p-tosyl-L-lizin klórmetilketon (TLCK), jódacetamid és 
a disuccinimidyl suberate (DSS) a Sigma (Németország) terméke 
volt. 
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PMN leukociták szeparálása 
Humán neutrofileket egészséges egyének perifériás véréből dextrá-
nos ülepítést követően Ficoll-Hypaque (Pharmacia, Uppsala, 
Svédország) grádiensen szeparáltuk (1). A PMN leukocitákat tartal-
mazó réteget Pasteur pipettával leszívtuk, PBS-ben mostuk, majd a 
vörösvértesteket hipotóniás lízissel, a trombocitákat többszörös mar-
ha-szérum albuminnal (BSA, Sigma, Dreisenhofen, Németország) 
végzett mosással eltávolítottuk. Az így szeparált leukociták>90% 
neutrofilt tartalmaznak (viabilitás>95%). 
IL-8INH preparálása 
Egészséges egyének perifériás véréből szeparált 2x10' PMN leu-
kocitát 30 percig 37 °C-on 0,5 ml PBS-ben inkubáltuk, és 1500 g-
vel 10 percig centrifugáltuk és a további vizsgálatokhoz a fe-
lülúszót használtuk. A különböző egyénektől származó 20 ml 
összegyűjtött felülúszót ismét centrifugáltuk (15000 g, 30 perc), 
ammónium-szulfáttal precipitálva koncentráltuk, és PBS-el diali-
záltuk. Az így elkészült felülúszót (fehérjetartalma 100 mg/ml) 
használtuk a további vizsgálatokhoz az IL-8 hatásainak befolyáso-
lásához, és a gátló fehérjét IL-8 inhibitornak (IL-8INH) neveztük 
el. A vizsgálatok egy részében az IL-8INH-1 tartalmazó PMN leu-
kocita felülúszót proteáz-inhibitorok, aprotinin (50 mg/ml), benza-
midin (5,0 mM), TLCK (5,0 mM) vagy jódacetamid (50 mM) je-
lenlétében preparáltuk. 
1L-8INH biológiai aktivitásának mérése 
PMN leukociták IL-8 által kiváltott kemotaxisát Boyden kamrában 
vizsgáltuk. A kamra felső része 2x10® PMN leukocitát tartalmazott 
RPMI 1640 médiumban, míg a kamra alsó része 0,1-20 nM IL-8-at 
tartalmazott, melyet 60 percig PBS-vel vagy koncentrált IL-8INH-
ral előinkubáltuk. A PMN leukocita kemotaxishoz 90 perces inkubá-
ciós időt és 4 pm nitrocellulóz filtert (Sartorius) használtunk. Az in-
kubációs idő után a filtert kivettük, hematoxilin-eozinnal megfestet-
tük, és a filter túloldalára átjutó sejteket megszámoltuk. Az IL-8INH 
specificitásának megállapítására az IL-8INH hatását vizsgáltuk a 
PAF (10 ' -10 " M), az FMLP (ÍO^-IO ' M) és a C5a (50-300 pg/ml) 
által kiváltott PMN leukocita chemotaxisra. 
A Candida albicans killing assayben 0.1-20 nM IL-8-cal stimu-
lált PMN leukocitát Candida albicans sejtekkel inkubáltuk 1:2 
arányban 90 percig, koncentrált IL-8INH jelenlétében vagy anélkül. 
A humán sejteket 1% Triton X hozzáadásával lizáltuk, majd az elölt 
Candida albicans sejteket metilénkék festéssel megszámoltuk. 
Az IL-8INH in vivo hatását egérfül modellen vizsgáltuk. A kísér-
leti állatokból négy csoportot képeztünk, csoportonként 6-6 egeret 
vizsgáltunk. Két csoportban az egerek mindkét fülének centrális te-
rületébe 10 ml 20 nM IL-8-cat fecskendeztünk, melyet előzőleg 60 
percig 37 °C-on 1:1 arányban PBS-sel vagy a standard körülmények 
között készült tömény IL-8INH-ral együtt inkubáltunk. Két további 
csoport állatainak fülébe 10 ml PBS illetve 10 ml IL-8INH injekciót 
adtunk. 4 órával a kezelést követően az egereket cervicalis dislocati-
oval elpusztítottuk, a füleket levágtuk, és szövettani feldolgozást vé-
geztünk. Hematoxilin-eozin festést követően 100-szoros nagyítás 
mellett az injekcióstú szúrási helye melletti 3 területen meghatároz-
tuk a látótérre jutó leukociták számát. A szövettani kiértékelést kód-
számmal ellátott metszeteken végeztük, és csak a kiértékelést köve-
tően történt azok beazonosítása. 
IL-8 radioligand kötési próba PMN leukocitán 
A radioligand kötési próbát laI-IL-8 radioligand felhasználásával 
korábbi közleményünkben megadott módon végeztük (1). PMN leu-
kocitákat (2xl07ml) 1% BSA-t, 20 mM HEPES puffert tartalmazó 
RPMI médiumban 1 nM ,aI-IL-8-cal inkubáltuk 90 percig 0 °C-on 
az IL-8INH jelenlétében illetve anélkül. A nem-specifikus kötés 
meghatározására a sejtek egy részét a 100-szoros túlsúlyban hoz-
záadott jelzetlen IL-8 jelenlétében inkubáltuk a radiofarmakonnal. A 
radioligand kötési próba végén a sejteket háromszor PBS-ben mos-
tuk, majd a radioaktivitást gamma számlálóban mértük. 
IL-8INH molekulasúlyának megállapítása 
Az IL-8 molekulasúlyának meghatározására az IL-8INH aktivitást 
tartalmazó PMN leukocita felülúszót 1:1 arányban 10 nM l2iI-IL-8-
cal inkubáltuk 60 percig 37 °C-on 1 mM jelzetlen IL-8 jelenlétében 
illetve annak hiányában, a keresztkötést létrehozó DSS jelenlétében 
(2,5 ill. 5,0 mM), valamint anélkül. Az inkubációt követően nátri-
um-dodecil-szulfát-poliakrilamid gélelektroforézist (SDS-PAGE) 
végeztünk, és autoradiográfiával tettük láthatóvá a ,aI-IL-8-at és az 
azzal DSS-sel keresztkötött fehérjéket. 
Eredmények 
Az 1L-81NH gátolja az IL-8 hatásait in vitro 
PMN leukocitákat emelkedő koncentrációkban IL-8-cal 
(5-20 nM) inkubáltuk IL-8INH (50 pg/ml) jelenlétében il-
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1. ábra 
PMN leukociták IL-8 által kiváltott kemotaxisa (A) és Candida albicans killing aktivitása (B) interleukin-8 
inhibitor jelenlétében ( • ) és anélkül ( • ) . A feltüntetett értékek az átlag ± SD-t jelentik négy független kísérlet alapján. 
108 
2. ábra 
IL-8 inhibitor (IL-8INH) hatása az IL-8 által kiváltott leukocita infiltrációra 
egérfülben. A: 20 nM IL-8, B: 20 nM IL-8 +50 pg/ml IL-8INH. 
Hematoxilin - eozin festés, lOOx 
aktivitását mértük. A PMN leukociták IL-8 hatására kiala-
kuló kemotaxisát és Candida albicans killing aktivitását a 
PMN leukociták felülúszójából preparált IL-8INH csak-
nem 100%-ban gátolja (1. ábra a, b). Az IL-8INHmég 
1:500 hígításban is szignifikáns mértékben gátolja a neut-
rofilek kemotaxisát. Az IL-8INH specificitását vizsgálva 
megállapítottuk, hogy az IL-8INH nem befolyásolja a 
PAF (1 pM-10 nM) és az FMLP (1 nM-1 mM) PMN leu-
kocitákra kifejtett kemotaktikus hatását (nem mutatjuk). 
Az II-81NH gátolja az IL-8 gyulladáskeltő hatását in vivo 
Egerek fülén 20 nM IL-8-cal IL-8INH jelenlétében és 
anélkül gyulladást váltottunk ki, és a kialakult neutrofil 
infiltrációt szövettani vizsgálattal határoztuk meg. 20 nM 
IL-8 hatására 4 óra alatt az egérfülben ödéma, és jelentős 
neutrofil beszűrődés alakult ki. Az 2. ábra mutatja az 
egérfülben IL-8 hatására kialakuló PMN leukocita infilt-
rációt IL-8INH jelenlétében és anél-
kül. Eredményeink szerint az IL-
8INH jelentősen gátolja az egérfül-
ben IL-8 hatására kialakuló neutro-
fil infiltráció kialakulását. 
Proteáz inhibitorok hatása az IL-
8INH gátló hatására 
Amikor az IL-8INH-1 PMN leuko-
citák felülúszójából proteáz inhibi-
torok (50 mg/ml aprotinin, 5,0 mM 
benzamidin, 5,0 mMTLCK vagy 
50 mM jódacetamid) jelenlétében 
preparáltuk, ez nem befolyásolta az 
IL-8INH gátló hatását az IL-8 által 
kiváltott neutrofil kemotaxisra. 
Ezen eredményünk arra utal, hogy 
az IL-8INH feltehetően nem az IL-8 
receptor sejtmembránról való prote-
olitikus leválásának (shedding) kö-
vetkezményeként képződik. 
Az IL-8INH hatása a l2SI-IL-8 kötés-
re PMN leukocitán 
Az IL-8INH hatásmechanizmusá-
nak megállapítására vizsgáltuk a 
l25I-IL-8 kötést PMN leukocitákhoz 
IL-8INH jelenlétében és anélkül. 
l2T-IL-8-at 37 °C-on különböző idő-
tartamig koncentrált IL-8INH jelen-
létében inkubáltuk, majd radioli-
gand kötési próbát végeztünk. Ered-
ményeink szerint 30-60 perces elő-
inkubációt követően az IL-8INH 
mintegy 70%-kal gátolja a l23I-EL-8 
receptorhoz történő kötését. Ez a 
vizsgálat arra utal, hogy az IL-8INH 
feltehetően hozzákötődik az IL-8-
hoz, és ezzel megakadályozza az 
IL-8 receptorhoz történő kötését (3. 
ábra). Amennyiben a kötési próba 
után adjuk az inkubációs médiumhoz az IL-8INH-t, akkor 
gátló hatást nem tapasztalunk, azaz az IL-8INH nem vi-
selkedik kompetítorként (nincs feltüntetve). 
Az IL-8INH molekulatömegének megállapítása 
Koncentrált IL-8INH-t és 125I-IL-8-at inkubáltuk a (fehér-
jék közti keresztkötést létrehozó) DSS különböző kon-
centrációval nagy feleslegben adott jelöletlen IL-8 jelen-
létében vagy anélkül. Az SDS-PAGE vizsgálatban (4. áb-
ra) a DSS-t nem tartalmazó oszlopokban (2, 5) csak a 
,2T-IL-8-nak megfelelő kDa csík és egy 80 kDa csík volt 
detektálható. A 80 kDa csík jelzetlen IL-8 hozzáadását 
követően (5-7 oszlopok) nem változik, ami arra utal, 
hogy ez a l!5I-IL-8 nem specifikus kötése valamely szé-
rum fehérjéhez. Western blot vizsgálattal ez a 80 kDa 
csík reagált anti-humán szérum albuminnal (HSA) (nem 
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3. ábra 
IL-8INH gátolja a 125I-IL-8 kötést PMN leukocitán. 
A feltüntetett adatok a gátlás mértékét ± SD-t tüntetik fel 
3 független kísérlet eredménye alapján. 
4. ábra 
IL-8INH és '"I-IL-8 keresztkötése. 
A PMN leukocita felülúszót 10 nM ,2T-IL-8-cal 
inkubáltuk jelöletlen IL-8 nélkül (2—4 sávok), 
vagy IL-8 jelenlétében (5-7 sávok), 
DSS nélkül (2,5 sáv), 2,5 mM DSS (3,6 sáv) 
vagy 5,0 mM DSS = (4,7 sávok) jelenlétében, 
majd SDS-PAGE vizsgálatot végeztünk. 
1: sáv: csak 10 nM ,25I-IL-8. 
nem-specifikus kötése HSA-hoz. A DSS-t is tartalmazó 
oszlopokban (3-4 illetve 6-7 oszlopok) azonban egy 60 
kDa extra csík is megjelenik, amelynek intenzitása jelzet-
len IL-8 hozzáadásával (6-7 csíkok) csökken, jelezvén, 
hogy a ,25I-IL-8 kötése ezen fehérjéhez specifikus. Az IL-
8INH molekulatömege ezek alapján (a 8 kDa IL-8 levo-
nását követően) mintegy 52 kDa. A nagy koncentráció-
ban feleslegben adott IL-9-at és DSS-t tartalmazó oszlo-
pokban (6-7 oszlopok) látott 16 kDa csík az IL-8 dimér-
nek felel meg, igazolván korábbi vizsgálataink eredmé-
nyét, amely szerint az IL-8 koncentráció-dependens mó-
don dimerizálódik. 
Megbeszélés 
Mivel a citokinek biológiai hatását a citokin és receptorá-
nak kifejeződésén túlmenően szolubilis inhibitorok, úgy-
mint szolubilis receptorok, receptor antagonisták vagy 
carrier proteinek is befolyásolják (5), vizsgáltuk, hogy 
PMN leukociták felülúszójában IL-8 hatását gátló inhibi-
tor (IL-8INH) kimutatható-e. 
Eredményeink arra utalnak, hogy a PMN leukociták fe-
lülúszója egy kb. 52 kDa EL-8INH fehérjét tartalmaz, 
amely gátolja a neutrofilek IL-8 által kiváltott kemotaxi-
sát és Candida albicans killing aktivitását in vitro, vala-
mint az IL-8 hatására kialakuló neutrofil infiltrációt in vi-
vő. Radioligand kötési próbák eredményei arra utalnak, 
hogy az IL-8INH hozzákötődik az IL-8-hoz, és ez a kötés 
megakadályozza az IL-8 receptorhoz való kötését. 
A citokin inhibitoroknak az a hatásmechanizmusa, 
hogy a szabad citokinekhez hozzákötődnek, és ezáltal 
megakadályozzák a ligand kötését a specifikus receptor-
hoz. A szolubilis citokin-kötő fehérjék lehetnek szolubi-
lis receptorok és nem receptor természetű carrier fehér-
jék. A szolubilis receptorok a membrán-kötött recepto-
rokból képződnek proteolizis, vagy egy külön szolubilis 
receptor szintézise (alternatív splicing) révén. Az álta-
lunk leírt IL-8INH feltehetően nem az IL-8 receptor 
proteolizis során lehasított extracelluláris része, mivel 
proteolitikus enzimekkel képződése nem gátolható. 
Ezen túlmenően, az IL-8 receptor egy 58 kDa fehérje, 
melyből az extracelluláris dómén kb. 15 kDa (15), így a 
IL-8INH 52 kDa molekula mérete sem felel meg IL-8 
receptor extracelluláris részének. Mivel az IL-8 receptor 
7 transzmembrán domént tartalmaz (15), egy „alternatív 
splicing" révén szintetizálódó szolubilis receptor képző-
dése is nagyon valószínűtlen. A szolubilis receptorokon 
túlmenően szérum és vizelet fehérjék is képesek bizo-
nyos citokineket megkötni, és azok hatását modulálni. 
Az általunk leírt IL-8INH is egy ilyen citokin-kötő fe-
hérje lehet, amely az IL-8-hoz kötődve gátolja biológiai 
hatását. Mivel az IL-8 hatékony gyulladáskeltő hatású 
citokin, az IL-8INH további biokémiai jellemzése és 
tisztított formában történő előállítása terápiás lehetősé-
get rejt magában. 
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A mannóz kötő receptorok szerepe a humán keratinociták 
Candida albicans killing aktivitásában 
Mannose-binding receptors are involved in killing 
Candida albicans by human keratinocytes 
SZOLNOKY GYŐZŐ DR., KEMÉNY LAJOS DR., KENDERESSY SZABÓ ANNA DR., 
KISS MÁRIA DR., BATA ZSUZSANNA DR., DOBOZY ATTILA DR. 
ÖSSZEFOGLALÁS 
Ismert, hogy a frissen szeparált humán keratinociták ké-
pesek in vitro körülmények közölt Candida albicans sejtek 
elölésére, a folyamat pontos mechanizmusa azonban nem 
tisztázott. Mivel a makrofágok mannóz receptorai szerepet 
játszanak a Candida sejtek elölésében, a szerzők célkitű-
zése volt annak vizsgálata, vajon hasonló mechanizmus 
működik-e a humán keratinocitáknál. Jelen vizsgálatuk-
ban bemutatják, hogy a humán keratinociták mind spon-
tán, mind pedig az UV-B, a-MSH és IL-8 által stimulált 
Candida killing aktivitása gátolható mannánnal vagy 
borjú szérum albuminhoz kötött mannóz molekulákat tar-
talmazó neoglycoproteinnel, ún. Man-BSA-val. A humán 
morfológ mannóz receptor ellenes poliklonális antitest a 
keratinociták sejtmembránját festette, míg a monoklonális 
ellenanyag esetén hasonlót nem figyeltek meg, ami kü-
lönbséget jelez a makrofágok mannóz receptorához ké-
pest. Az eredmények alapján a humán keratinociták felszí-
nén a Candida elpusztítás folyamatában résztvevő man-
nóz kötő struktúrák jelenléte valószínűsíthető, melyek 
szerkezete nem teljesen azonos a makrofág mannóz recep-
toréval. 
Kulcsszavak: 
epidermisz - sarjadzógomba fertőzés -
védekezés 
SUMMARY 
Human keratinocytes, freshly separated from the epider-
mis are known to be able to kill Candida albicans in vitro, 
but the mechanism of killing is not yet understood. 
Because mannose receptors are involved in the phagocy-
tosis and killing of Candida by macrophages, the authors 
were interested to examine whether a similar mechanism 
exists in keratinocytes. Here they demonstrate that both 
the spontaneous and the UV-B light, a-MSH and IL-8 
stimulated Candida killing activity of keratinocytes could 
be inhibited by incubation with mannan or a a neoglyco-
protein, containing mannosylated bovine serum albumin 
(Man-BSA). Polyclonal antibodies directed against the 
human macrophage mannose receptor stained keratinocy-
tes along the cell membrane, but no staining was obser-
ved using the monoclonal antibody (mAbls), indicating 
that the human keratinocyte mannose-binding receptor 
differs from the human macrophage mannose receptor. 
These results suggest that human keratinocytes have 
mannose-binding receptors that are structurally different 
from macrophage mannose receptor but similar to their 
characteristics. They are actively involved in the killing of 
Candida albicans. 
Key words: 
epidermis - yeast infection -
host defence 
A Candida infekciók jelentős orvosi problémát jelente-
nek, de a sarjadzógombák elleni védekezés mechanizmu-
sa még nem teljesen tisztázott. A humán szervezet Candi-
da albicans (C. albicans) elleni védekezésben a makrofá-
gok és polimorfonukleáris leukociták fagocitózisának és 
ölő tevékenységéenk fontos szerepe van. Halmy és mun-
katársainak vizsgálata alapján a leukociták ezen funkciója 
stimulálható griseofiilvin, Candida és Trichophyton .vakci-
na segítségével (11), valamint fokozódokk itrakonazol, 
ketokonazol és flukonazol kezelés hatására (12). A kerati-
nociták is fontos szerepet töltenek be sarjadzógomba elle-
nes védekezésben. Már korábban közöltük, hogy a frissen 
szeparált humán keratinociták képesek a Candida albi-
cans sejtek elölésére (4). Ez az aktivitás nagymértékben 
fokozható UV-B (S), a-melanocita stimuláló hormon 
(a-MSH) (6) és interleukin-8 (IL-8) (14) segítségével tör-
tént stimulációval. Az interleukin-1 (IL-1), prosztaglandin 
E2 (PGE2), és a trombocita-aktiváló faktor (PAF) részvé-
telét szintén kimutatták a Candida albicans killing aktivi-
tásban (7, 20). A Candida sejtfal fő komponensei a.mán~~ 
nán (egy a-kötött mannózpolimer), glukán (egy Bekötött 
elágazó láncú glükóz poliszacharid) és kitin (egy cellulóz-
1S1 
szerű biopolimer, amely főleg N-acetil-D-glükózamint 
tartalmaz) (3). Több jelentős közlemény alapján világossá 
vált, hogy a mannóz receptorok részt vesznek a makrofá-
gok Candida albicans ölő mechanizmusában (9, 17, 18, 
19). A Candida albicans sejtek tapadása a makrofágok 
felszínéhez mind a sarjadzógomba sejtek felszíni mannán-
ját, mind pedig a makrofágok mannóz receptorát igényli. 
A makrofágok sejtfelszíni mannóz receptorai aktívan részt 
vesznek a különböző Candida törzsek, csakúgy mint más 
mikroorganizmusok, így a Pseudomonas (24), Pneumo-
cystis carinii (10), Mycobacterium avium (2) elölésében 
és fagocitőzisában. 
A mannán vagy Man-BSA kötődése a makrofágok fel-
színi specifikus mannóz receptorához gátolta a Candida 
fagocitózist és a killing aktivitást, azt sugallva, hogy a 
sarjadzó sejtek tapadása a makrofógok felszínéhez a 
Edling szempontjából nélkülözhetetlen (17, 18). Mivel a 
humán keratinociták a monocitákkal és makrofágokkal 
azonos sejtfelszíni antigégeneket képesek megjeleníteni 
(13), aira kerestük a választ, vajon a humán keratinociták 
a makrofágokéhoz hasonlóan, mannóz receptorok segítsé-
gével végzik-e a Candida albicans killing tevékenységü-
ket. 
Anyagok és módszerek 
Sejtek: Humán keratinocitákat egészséges, plasztikai sebészeti 
beavatkozáson átesett betegek bőrébői nyertünk. A szubkután szöve-
tek és a retikuláris detmisz nagy részének eltávolítása után a szövet-
darabokat kis csíkokra vágtuk és 0,25% tripszinben (Sigma, Mün-
chen, Németország) inkubáltuk 12 órán keresztül 4 °C-on. Az epi-
dermiszt ezután lefejtettük a dermiszről és sejtszuszpenziót készítet-
tünk (10*/ml) ún. Dulbecco's modified Eagle médium (DMEM) 
(Gibco, Eggenstein, Németország) oldatban, amit 20%-os borjú szé-
rum albuminnal (FBS), 20 mM Hepes puferrel, 100 U/ml penicillin-
nel és 100 pg/ml streptomycinnel egészítettünk ki (Gibco). Az élet-
képes sejtek aránya a tripán kék festés alapján 85% volt. A szeparált 
sejteket immunohisztokémiai módszerekkel ún. citospin preparátu-
mok (Cytospin, Shandon-EUiot, Frankfurt, Németország) segítségé-
vel jellemeztük. A keratinocitákat az összes citokeratin egy epitőpjá-
val reagáló, Lu 5 monoklonális antitesttel (Boehringer, Mannheim, 
Germany), a Langerhans sejteket anti-CDla antitesttel (Boehringer), 
az endotél sejteket a von Willebrand factor (vWf) molekulától elté-
rő, az endotélsejtekre specifikus, egy 200 kD-os antigénnel reagáló 
ún. BMA 120 antitesttel (Behring Werke Marburg, Németország) je-
löltük (1). A szeparált sejtek immunhisztokémiai vizsgálata azt mu-
tatta, hogy a sejtek 95%-a keratinocita volt és a maradékot fibrob-
lasztok és melanociták alkották. Nem tudtunk sem Langerhans, sem 
pedig endotél sejtet kimutatni. Kísérleteink egy csoportjában (gátlás 
egyéb szénhidrátokkal) HaCat sejteket használtunk. A HaCat sejte-
ket 10% borjú savót (FBS) tartalmazó DMEM oldatban tenyésztet-
tük. A Candida albicans (Candida albicans CBS 0656) sejteket 
Sabouraud agaron tenyésztettük, majd friss agaira oltottuk át 24 órá-
val a felhasználás előtt. A Candida sejteket PBS-sel történő mosás-
sal választottuk le a táptalajról, majd a sarjadzógomba sejteket he-
mocitometerben mikroszkóp alatt számoltuk meg. 
A Candida albicans killing vizsgálata: Az eredetileg leukociták-
nál alkalmazott módszer módosított változatát alkalmaztuk a kerati-
nociták és HaCat sejtek Candida killing aktivitásának mérésére (4). 
Röviden összefoglalva, 10* humán keratinocitát 2x10* Candida al-
bicans sejttel együtt vagy Candida albicans sejteket egyedül (kont-
roll) inkubáltunk DMEM oldatban 1 ml össztérfogatban 4 órán ke-
resztül 37 °C-on, 5% COj-ot tartalmazó, 100%-os relatív páratartal-
mú levegőjű termosztátban.' Az inkubációs idő letelte után a sejteket 
Triton X-100 (1%) (Sigma) oldattal kezeltük 5 percen keresztül 4 
°C-on azért, hogy a hámsejteket elroncsoljuk. Ezek után a Candida 
albicans sejteket metilén kék (0,1%) oldattal festettük 45 percen ke-
resztül 4 °C-on és az elölt, élettelen Candida sejtek számát mikrosz-
kóp alatt hemacitométer segítségével megszámoltuk. Az elölt Candi-
da sejtek számát úgy határoztuk meg, hogy kivontuk a kontroll 
elegyben lévó élettelen Candida sejtek számát a reakcióelegyben lé-
vő összes elpusztult Candida sejtek számából. Az ölő aktivitást az 
elölt Candida sejtek százalékos aránya adja meg. Azért, hogy meg-
bizonyosodjunk a metilén kék módszer pontosságáról, külön kísérle-
tekben meghatároztuk a sarjadzó sejtek kolóniaformáló egységeinek 
számát (CFU) (24) párhuzamosan a Candida albicans sejtszámmal. 
Az életképes sejtek és a kolóniaformáló egységek száma jól korre-
lált egymással a két vizsgálat során (r = 0,984, p<0,05). 
A Candida killing modulációja: A keratinocita szuszpenziókat 
290-370 nm-es 220 mJ/cm2 energiájú UV-B fénnyel sugaraztuk be 
1 percig 30 cm magasról Saalman-SUP lámpa (Gethard Saalman, 
Herford, Németország) segítségével. Az életképes sejtek aránya so-
hasem esett 80% alá. UV-B besugárzás után a keratinocitákat 
DMEM oldatban 37 °C-on 5% C02-tartalom mellett 3 órán keresz-
tül inkubáltuk a fennt leírt ún. Candida killing assay elótt. Más kí-
sérletekben a keratinocitákat 12 órán keresztül 2x10* M rekombi-
náns humán IL-8-cal (Hermann Biermann, Bad Nauheim, Germany) 
vagy 20 pg/ml a-MSH-val (Sigma) 1 órán kersztül stimuláltuk a kil-
ling assay előtt. A leírt kísérleti körülmények a stimuláció tekinteté-
ben optimálisnak bizonyultak korábbi kísérleteinkben. 
A Candida killing aktivitás gátlása szénhidrátokkal: 100 vagy 500 
pg/ml mannára (Sigma, >99% tiszta) vagy Man-BSA-t (E/Y Labs, 
San Mateo, CA, USA) oldottunk fel DMEM oldatban majd humán 
keratinociták és Candida sejtek elegyéhez adtuk, hogy megfigyeljük 
a killing aktivitást gátló hatásukat. Számos kísérletben, ahol HaCat 
sejteket használtunk, 500-2000 pg/ml koncentrációjú DMEM-ben 
oldott mannára, fruktőzt, szahaiózt, valamint dextrózt (Sigma) alkal-
maztunk a killing aktivitás gátlásának megítélésére. 
Immunhisztokémia: A bőrblopszlás anyagokat plasztikai sebészeti 
műtéten átesett betegekből nyertük. A biopsziás anyagokat ún. krio-
mátrixba (Shandon, Life Sciences International, Anglia) ágyaztuk-
be, 7 pm-es vastagságú metszeteket vágtunk, majd acetonban fixál-
tunk (10 perc, 4 °C). A metszeteket humán makrofág mannóz recep-
tor ellenes monoklonális antitestekkel (mAbu, egér IgG,) és tisztí-
tott makrofág mannóz receptor ellen termeltetett kecske savóval 
(mindkettőt Prof. Philip D. Stahltól kaptuk). Az elsődleges antites-
tekkel (l:50-es hígítás) és a megfelelő kontroll antitestekkel szoba-
hőmérsékleten végzett 1 órás inkubációt követően a biotinnal konju-
gált másodlagos antitestekkel inkubáltunk és ezután felhasználva a 
DAKO Strept ABC komplex kitjét és protokolját (DAKO A/5), Dá-
nia) streptavldin-biotin peroxidázt adtunk a rendszerhez. 3-amino-9-
etilkarbazolt (AEC, Sigma) használtunk peroxidáz szubsztrátként A 
metszeteket ezután hematoxilinnel festettük. 
Statisztikai analízis: Kétmintás t-próbát alkalmaztunk, ahol p< 
0,05 volt a szignifikancia szint. Variancia analízissel határoztuk meg 
a Candida albicans sejtszámok és a kolőniaformáló egységek közöt-
ti korreláció szignifikanciáját. 
Eredmények 
A humán keratinociták spontán Candida ölő aktivitását 
több mint 50%-kal csökkentette a mannán 100 pg/ml és 
500 pg/ml koncentrációkban, amely kifejezett gátló hatást 
jelez (1. a. ábra, az oszlopok első csoportja). Az a-MSH, 
IL-8 vagy UV-B sugárzással való kezelés mintegy három-
szorosára növelte egyenként a Candida ölő aktivitást 
(7. a. ábra, szürke oszlopok). A mannánnal történő inku-
báció a stimulált killing aktivitás százalékos arányának 
csökkenéséhez vezetett (7. a. ábra, második, harmadik és 
negyedik csoportja az oszlopoknak). A mannán gátló hatá-
sa jobban érvényesült 500 pg/ml koncentrációban mint 
100 pg/ml-es dózisban. 100 pg/ml és 500 pg/ml-es kon-
centrációjú Man-BSA a mannához hasonló módon befo-
lyásolta a spontán killinget (7. b. ábra, az oszlopok első 
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• 100 pg/ml Man-BSA 500 pg/ml Man-BSA 
1. a. ábra 
100 pg/ml és 500 pg/ml mannán hatása a spontán és az a-MSH, IL-8 és 
UV-B stimulálta keratinocita Candida killingre. A mannán mindegyik esetben 
szignifikánsan csökkenti az elpusztított Candida sejtek 
%-os arányát. (n=6, * jelzi p<0.05) 
mutatott a dermiszben, de pozitív festő-
dést kaptunk a keratinociták felszínén 
is, leginkább a szuprabazális rétegben 
(2. b. ábra). Mindkét kontroliban gyen-
ge, diffúz, citoplazma festést kaptunk 
mind a dermiszben, mind pedig az epi-
dermiszben (az eredményeket nem mu-
tatjuk), amelyek azt mutatják, hogy fes-
tésünk specifikus volt. Ezek az eredmé-
nyek amellett szólnak, hogy a keratino-
cita mannóz kötő receptor különbözik a 
makrofág mannóz receptortól, de struk-
turális hasonlóság van köztük. 
Megbeszélés 
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500 pg/ml Man-BSA 
1. b. ábra 
100 pg/ml és 500 pg/ml Man-BSA hatása spontán és az a-MSH, IL-8 
és UV-B stimulálta keratinocita Candida killingre. A Man-BSA mindkét 
koncentrációban kifejezetten gátolta az ölő aktivitást (n=6, * jelzi p<0.05) 
a mannánénál nagyobb gátló hatást mutatott az aktivált 
killing tevékenységet vizsgálva. (7. b. ábra, második, har-
madik és negyedik csoportja az oszlopoknak.) Eredmé-
nyeink összhangban állnak a makrofágokkal végzett kí-
sérletekkel (17). Korábbi munkánkban hasonló eredmé-
nyekhez jutottunk HaCat keratinocita sejtvonallal (8). 
Azért, hogy összehasonlítsuk a különböző szénhidrátok a 
Candida ölő tevékenységre kifejtett gátló hatását külön-
böző koncentrációban (100 pg/ml-2000 pg/ml) vizsgáltuk 
a szaharózt, a fruktózt, a dextrózt és a mannánt a HaCat 
sejtek esetén. A megegyező koncentrációkban a mannán 
képviselte a legkifejezettebb gátló hatást, mindazonáltal 
minden egyes szénhidrát gátolta valamilyen mértékben a 
killinget (az eredményeket nem ábrázoljuk). 
A humán makrofág mannóz receptorra specifikus mo-
noklonális antitest (15) tisztán festett a dermiszben egye-
dülálló sejteket, melyek feltehetően makrofágok, de nem 
voltak pozitív festődésű sejtek az epidermiszben (2. a. áb-
ra). A humán makrofág mannóz receptor ellen termeltetett 
poliklonális antitesttel történő festés hasonló mintázatot 
Sok patogén mikroorganizmus, mint 
például a Candida albicans elleni véde-
kezés mechanizmusa még nem teljesen 
tisztázott. A bőr infekciója során a 
komplex folyamatban a makrofágok és 
polimorfonukleáris leukociták is aktí-
van részt vesznek ölő, valamint fagoci-
táló tevékenységük révén. Krónikus re-
cidiváló Candida fertőzésekben a leu-
kociták csökkent aktivitása mutatható 
ki, mely azonban fokozható (11). Ko-
rábban bemutattuk, hogy a humán epi-
dermisz-sejtek Candida albicans ölő te-
vékenységgel rendelkeznek (4). A sej-
tek, amelyek ezért felelősek, a keratino-
citák. Jelen tanulmányunkban hasonló 
eredményeket kaptunk a korábban al-
kalmazott körülmények mellett. A hu-
mán epidermális keratinociták mellett a 
humán immortalizált keratinocita sejt-
vonal (HaCat) szintén hasonló hatás-
fokkal fejt ki Candida albicans ölő ak-
tivitást. Mind a spontán, mind pedig a stimulált Candida 
ölő aktivitás gátolható a PAF antagonista BN 52021-gyei, 
indomethacinummal és kortikoszteroidokkal, ami azt mu-
tatja, hogy az arahidonsav-kaszkád részt vesz az ölő fo-
lyamat mechanizmusában (7). 
A humán makrofág mannóz receptor egy jól jellemzett 
ligand kötő struktúra. Ezen mannóz receptorok mediálják 
a különböző glikoproteinek endocitózis útján történő eltá-
volítását (mint például a neutrofil granulociták enzimei, a 
szöveti típusú plazminogén aktivátor (22), glükocerebro-
zidáz (23), ricin (16), az IgE felvételét (21) és részt vesz-
nek különböző mikroorganizmusok fagocitózisában (25). 
Korábbi tanulmányainkban kimutattuk, hogy a humán 
keratinociták Candida albicans ölő tevékenysége fokoz-
ható UV-B sugárzás, a-MSH és IL-8 segítségével. Jelen 
közleményünkben bemutattuk, hogy a mannán és a Man-
BSA hatásos gátlószerei mind a spontán, mind pedig az 
UV-B, a-MSH és IL-8 stimulált Candida ölő aktivitásá-
nak ugyanúgy frissen szeparált keratinociták mint HaCat 
sejtek esetében. Egyéb szénhidrátokkal végzett kísérlet 
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Makrofág mannóz receptor ellenes antitestekkel festett normál 
humán bőr metszetek. A monoklonális antitest néhány dermális 
makrofág típusú sejtett festett (nyíl) (a), míg a poliklonális 
ellenanyag a dermális sejtek mellett főleg a szuprabazális 
keratinocitákat festette (b). (a vonal 25 pm-es) 
alapján a Candida ölő aktivitás gátlásában kifejtett hatá-
sosság a következő sorrend szerint alakult: mannán > 
dextróz > szaharóz > fruktóz. Eredményeink jó összhang-
ban állnak azon adatokkal, melyek a makrofágok Candida 
ölő aktivitásának gátlását igazolják mannán és Man-BSA 
segítségével (17, 18-). Az a tény, hogy a poliklonális ellen-
anyag diszkrét keratinocita membrán festést mutatott, va-
lamin a monoklonális ellenanyagot alkalmazva nem kap-
tunk jelölést a keratinocitákon, azt sugallja, hogy a ma-
krofág mannóz receptoroktól eltérő struktúrával állunk 
szemben keratinociták esetében. 
Első ízben mutatjuk be a humán keratinociták mannóz 
kötő receptorának jelenlétét és ezzel együtt élettani jelentő-
ségét a Candida fertőzés elleni védekező mechanizmusban. 
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(igazgató: Dóbozy Attila dr., egyetemi tanár) 
A humán keratinocita mannóz kötő receptorok jellemzése 
Characterization of human keratinocyte mannose-binding receptors 
SZOLNOKY GYŐZŐ DR., KEMÉNY LAJOS DR., KENDERESS Y SZABÓ ANNA DR., 
KISS MÁRIA DR., BATA ZSUZSANNA DR., DOBOZY ATTILA DR. 
ÖSSZEFOGLALÁS 
A szerzők korábban kimutatták, hogy a spontán és a sti-
mulált Candida killing aktivitás gátolható mannánnal 
vagy mannózzal konjugált borjú szérum albuminnal 
(Man-BSA), valamint immunhisztokémiai vizsgálatok so-
rán a keratinociták festődnek poliklonális humán makro-
fág mannóz receptor ellenes ellenanyaggal. A kötő struk-
túrákjellemzésében, a radioligand kötési próbák során a 
radioaktívon jelzett '"I-Man-BSA kötődését a humán ke- • 
ratinocitákhoz a rendszerhez adott, nem jelzett liganddal 
(mannán) koncentráció függő módon tudták gátolni. A kö-
tési próbák adatai alapján az MxN-FÍT program segítsé-
gével iín. Scatchard analízis során egy K0 = 1.4x10* M 
disszociációs állandóval és B^, = 1x10 sejtfelszíni sűrű-
séggel jellemzett receptort határoztak meg a humán kera-
tinociták felszínén. 37 °C-on a '"l-Man-BSA kötése a hu-
mán keratinocitákhoz időkinetika szerint változik, vala-
mint ecetsavas kezeléssel majdnem 90%-ban eltávolítha-
tó. 'Ul-Man-BSA kötő kapacitás szignifikánsan csökkent a 
keratinociták trípszines előkezelése után és a ligand kötés 
Ccr* függőnek bizonyult. 
Kulcsszavak: 
epidermisz - sarjadzógomba fertőzés 
- védekezés 
SUMMARY 
The authors have earlier described that both spontaneous 
and stimulated Candida albicans killing of human kerati-
nocytes could be inhibited by mannan or mannosylated 
bovine serum albumin (Man-BSA). In immunohistochemi-
cal studies polyclonal antibodies against the human ma-
crophage mannose receptor stained keratinocytes. In ra-
dioligand binding studies, the binding of ml-Man-BSA to 
human keratinocytes was inhibited by mannan in a con-
centration-deperident manner. Analysis of the binding da-
ta with a nonlinear curve-fitting program (MxN-FlT) re-
vealed the presence of mannose-binding receptors with a 
Kd of 1.4x10* M and B^ of 1x10' binding sites per cell 
on human keratinocytes. The binding ofI-Man-BSA to 
keratinocytes proved to be time-dependent and acid preci-
pitable to almost 90% at 37 °C. The capacity to bind mI-
Man-BSA was significantly decreased after trypsin treat-
ment of keratinocytes and the ligand binding was Ccr* 
sensitive. 
Key words: 
epidermis - yeast infection 
- host defence 
Habár a Candida infekciók jelentős orvosi problémát je-
lentenek, a sarjadzógomba sejtek elleni védekezés me-
chanizmusa még nem .teljesen tisztázott. A mannóz recep-
tor köztudottan kifejeződik a makrofágokon, és á komp-
lemettől független, sejtfalukban polimerizált mannóz 
struktúrákat hordozó patogén mikroorganizmusok elleni 
védekezésben vesz részt a kórokozó elölése és fagocitó-
zisa útján. 
A makrofágoknál leírtakhoz hasonlóan a mannán vagy 
Man-BSA hozzáadása gátolta a keratinociták Candida kil-
ling aktivitását, azt sugallva, hogy a sarjadzó sejtek elleni 
védekezésben szerepe van a mannóz kötő struktúráknak. 
A sarjadzó sejtek tapadása a makrofágok felszínéhez a 
mannóz receptorokon keresztül a killing szempontjából 
nélkülözhetetlen (8). Immunhisztokémiai vizsgálatok azt 
mutatták, hogy a poliklonális humán mannóz receptor el-
lenes antitestek festik az epidermisz keratinocitáit. Ezek 
az eredmények a keratinociták felszínén lévő mannóz kö-
tő struktúrák létezését támasztják alá. Jelen munkánkban a 
humán keratinociták mannóz kötő receptorait jellemez-
zük. 
Anyagok és módszerek 
Sejtek: Humán keratinocitákat egészséges, plasztikai sebészeti 
beavatkozáson átesett betegek bőréből nyertünk. A szubkután szöve-
tek és a retikuláris dermisz nagy részének eltávolítása után a szövet-
darabokat kis csíkokra vágtuk és 0,25% tripszinben (Sigma, Mün-
chen, Németország) inkubáltuk 12 órán keresztül 4 °C-on. Az epi-
deimiszt ezután lefejtettük a dermiszről és sejtszuszpenziót készítet-
tünk (lOVmi) ún. Dulbecco's modified Eagles médium (DMEM) 
(Gibco, Eggenstein, Németország) oldatban, amit 20%-os borjú szé-
rum albuminnal (FBS), 20 mM Hepes pufferrel, 100 U/ml penicil-
linnel és 100 mg/ml streptomycinnel egészítettünk ki (Gibco). Az 
életképes sejtek aránya a tripán kék festés alapján 85% volt. 
Radioligand kötési próba: A radioligand kötési próbákat frissen 
szeparált humán keratinocitákon végeztük. A Man-BSA-t a chlora-
3 
mine T módszer (13) segítségével jelöltük '"I izotóppal, és 1.0x10* 
cpm/mg specifikus aktivitás mellett használtuk. 
A szaturációs vizsgálatok során 5x10' keratinocitát inkubáltunk 
növekvő koncentrációjú '-'I-Man-BSA-val (lö'-2x10* cpm/lyuk) 1% 
BSA-t, 10 mM Hepes-t és 1.2 mM CaCl,-ot 400 ml végső térfogat-
ban. Az inkubációt 90 percen keresztül 4 °C-on végeztük állandó rá-
zás mellett és kétszeres jéghideg PBS mosással állítottuk le. A sejt-
asszociált radioaktivitást Packard gamma-spektrométerrel (Packard 
Instrument Co. Inc., Downers Grove, 111, U.S.A.) mértük. A nem 
mannán specifikus (mannántói független) kötést 3 mg/ml jelöletlen 
mannán jelenlétében mértük. A mannán specifikus kötést a teljes kö-
tés és a nem mannán specifikus '"I-Man-BSA kötés különbsége ad-
ja. Adataink összesen hat különböző kísérletből származnak. A 
disszociációs konstans(Á"D) és a sejtfelszínre jutó átlagos kötőhelyek 
számának (flmax) meghatározásához a szaturációs görbéket egy kom-
puteres program, az ún. MxN-FIT (2) segítségével elemeztük. 
A kompetíciós vizsgálatokban a sejteket állandó koncentrációjú 
'-'I-Man-BSA-val (6x10-' cpm/lyuk), valamint növekvő koncentrá-
ciójú (10-3000 pg/ml) jelöletlen liganddal inkubáltuk. A kompetí-ci-
ós vizsgálatokat a szaturációs vizsgálatoknál leírt körülmények kö-
zött végeztük. 
115I-Man-BSA intemalizációja (bekebelezése): Módosított radioli-
gand kötési próbát végeztünk 37 °C-on (3, 4) azért, hogy meghatá-
rozzuk a '"I-Man-BSA bekebelezésének kinetikáját. A keratinocitá-
kat (5xl0'/lyuk) 4x10* cpm/lyuk '"I-Man-BSA-val inkubáltuk 3 
mg/ml mannán jelenlétében 400 ml össztérfogatban. Különböző idő 
intervallumok után (10, 20 vagy 30 perc) a kötési próbát négyszeri 
jéghideg PBS-es mosással állítottuk le és a sejthez kötött radioakti-
vitást gamma-számlálóval mértük. A mannán specifikus kötést a tel-
jes kötés és a nem mannán specifikus kötés különbsége adja. 3 per-
cig ecetsavval (pH 3) kezeltük, majd kétszer jéghideg PBS-sel mos-
tuk a sejteket a radioligand kötési próbát követően azért, hogy meg-
határozzuk, hogy a sejthez kötött radioaktivitás hányad része került 
a sejten belülre. Az ún. savazással el nem távolítható radioaktivitás a 
sejt belsejében lévő ligandot jelenti, míg a savazással eltávolítható 
radioaktivitás a sejtfelszínhez kötött ligadnak megfelelő (1). 
A Man-BSA kötések Ca5*-függőségének meghatározásához a ra-
dioligand kötési próbákat 37 °C-on végeztük, melynek során a sejte-
ket 10 mM etilén glikol-bisz(B-aminoetil éter)-N,N,N',N'-tetraecet-
savval (EGTA) (Sigma) 30 percig inkubáltuk a kötési próba előtt. 
A mannóz kötő receptorok tripszin érzékenységének vizsgálata 
során a sejteket 10 mg/ml tripszinnel (I. típusú marha hasnyálmirigy, 
Sigma) inkubáltuk 10, 60 vagy 120 percig a kötési próba elvégzése 
előtt. 
Eredmények 
A radioligand kötési próbákat l23I-Man-BSA segítségével 
4 °C-on végeztünk, hogy megakadályozzuk a ligand inter-
nalizációját és degradációját. A kompetíciós vizsgálatok 
azt mutatták, hogy a jelöletlen mannán dózisfüggő módon 
gátolta a l23I-Man-BSA kötését a frissen szeparált humán 
keratinocitákhoz, támogatva azt, hogy a ,25I-Man-BSA kö-
tés mannán specifikus. (1. ábra). 
Növekvő koncentrációjú 12íI-Man-BSA-val történő in-
kubáció során egyre emelkedő jelzett ligand kötést figyel-
tünk meg (2. ábra). A kötési próbák adatait egy számító-
gépes programmal (MxN-FIT) elemeztük és ennek során 
a mannóz kötő felszíni struktúrák disszociációs állandójá-
nak (ATd) 1.4X10 ® M-t, az egy sejtfelszínre jutó átlagos re-
cepetorszám (őmax) kiszámolásakor 1x10* kötőhely/sejt ér-
téket kaptunk. 
Más kísérletekben a keratinocitákat állandó koncentrá-
ciójú (4xl06 cpm/lyuk) l23I-Man-BSA-val egyedül vagy 3 
mg/ml mannánnal együtt inkubáltuk 37 °C-on 10, 20 és 
30 perces időintervallumokban. A mannán specifikus ra-
dioaktivitást úgy határoztuk meg, hogy a mannán nélkül 
2000 
Mannán koncentráció (pg/ml) 
1. ábra 
'"I-Man-BSA kötési próba: kompetíciós vizsgálat. 
Állandó koncentrációjú l25I-Man-BSA mellett emelkedő 
dózisú mannán koncentráció függő módon gátolta a jelölt 
ligand kötődését a keratinocitákhoz. (n=6) 
AD = 1.4 x 10 » M 
flm.i " 10 4 receptor /se j t 
Összes ( x 10 mol/1) 
2. ábra 
'"I-Man-BSA kötési próba: szaturációs vizsgálat. 
Emelkedő koncentrációjú '"I-Man-BSA inkubációja 
után komputeres Scatchard-analízist végeztünk, 
amely a kötési állandó (KD) és a receptorszám (őmix) 
értékét adja meg. (n=6) 
mért radioaktivitás (teljes kötés) értékéből kivontuk a 
mannán jelenlétében mért radioaktivitást (nem mannán 
specifikus kötés) (3. ábra). A 10 perc után mért nem man-
nán specifikus radioaktivitás mértéke nem változott jelen-
tősen a további 37 °C-s inkubáció (20, 30 perc) (3. ábra, 
szaggatott vonal) során, míg a mannán specifikus kötés 
értéke emelkedett a hosszabb inkubáció mellett (3. ábra, 
pontozott vonal). 10 perces inkubáció után nem volt kü-
lönbség a savval eltávolítható és a sav-stabil specifikus ra-
dioaktivitásban (4. ábra, üres és szürke oszlopok). 30 per-
ces inkubációt követően számottevő növekedést figyel-
tünk meg a teljes mannán specifikus kötés esetén, amely-
nek majdnem 90%-át azonban savazással el tudtuk távolí-
tani. (4. ábra, fekete és üres oszlopok), míg a sav-stabil 
rész csak kicsiny változást mutatott (4. ábra, szürke oszlo-
pok). Ez azt sugallta, hogy a 1I5I-Man-BSA döntő hányada 
sejtfelszínhez kötődő maradt és csak csekély része került 
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Humán keratinociták radioligand kötési próbája 37 °C-on. 
A kötést 10, 20 és 30 perc után vizsgáltuk. 
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4. ábra 
l25I-Man-BSA kötődése humán keratinocitákhoz 
nagymértékben csökken ecetsavas (pH 3) kezelés hatására 
37 °C-on. Ez azt mutatta, hogy a ligand nagy része nem 
jut be a keratinociták belsejébe. (n=4) 
A szénhidrát felismerő receptorrész Ca2*-függőségének 
meghatározására vizsgáltuk egy kelátképző ágens, az 
EGTA hatását. Ahogy az 5. ábra mutatja, az EGTA majd-
nem teljesen gátolta a radioligand kötést jelezve, hogy a 
kötés Ca2*-függő. Bár kísérleteinkben a keratinocitákat a 
killing és a kötési próbák előtt a szeparálás során tettük ki 
tripszin hatásának, eredményeink alapján állíthatjuk, hogy 
Kontroll EGTA kezel ÍJ 
5. ábra 
Ca2* elvonás hatása a 123I-Man-BSA kötésre 37 °C-on. 
10 raM EGTA kezelés nagymértékben csökkentette 
a jelzett ligand kötődését, ami jelezte a Ca24 függőséget. 
(n=4, * jelzi p<0.01) 
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6. ábra 
A korlátozott proteolízis csökkenti a l23I-Man-BSA kötést 
37 °C-on. A kötést 0, 10, 60 és 120 perces inkubációs idők 
után vizsgálva kifejezett, idő függő csökkenést láttunk. 
(n=4, * és ** jelzi a szignifikáns csökkenést 
(p<0.05 és p<0.001)) 
a receptorok gyorsan visszanyerik eredeti funkciójukat. 
Valójában Kang és Schlesinger kimutatták, hogy 4 °C-on 
végzett tripszines inkubáció során elvesztett receptor akti-
vitást a sejtek gyorsan, mintegy 10 perc alatt visszanyerik 
37 °C-on (7). Összhangban a korábbi megfigyelésekkel 
amelyeket makrofágokkal kapcsolatos vizsgálatok során 
szereztek (16), a kötőhelyek igen érzékenynek bizonyul-
tak tripszinre. A tripszines előkezelés egy időfüggő csök-
kenést váltott ki a radioaktívan jelölt ligand kötődése so-
rán (6. ábra). A sejtek 120 perces tripszines előkezelése a 
radioligand kötés több mint 90%-os elvesztését eredmé-
nyezte. 
Megbeszélés 
A humán makrofág mannóz receptor egy jól jellemzett li-
gand kötő struktúra. Ezen mannóz receptorok mediálják a 
különböző glikoproteinek endocitózis útján történő eltá-
volítását és részt vesznek számos mikroorganizmus fago-
citózisában. Maródi és munkatársai közölték (8, 9), hogy 
a makrofágok képesek a Candida albicans sejtek elölésé-
re és a mannóz receptorok aktív szerepet játszanak a ma-
krofágok ezen ölő tevékenységében. A felületi mannóz re-
ceptorok expressziója csökkenthető a makrofágok Bacil-
lus-Calmette-Guerin-x\t\ (4) vagy LPS és phorbol észte-
rekkel (15) történő kezelése során, valamint fokozható 
kortikoszteroidok, PGE:, és IL-4 segítségével (18, 15, 
19). Maródi és munkatársai (10, 11) kimutatták, hogy a 
makrofágok Candida ölő aktivitása interferon-y (IFN-y) 
segítségével fokozható. 
A keratinociták mannóz kötő receptorának jellemzőit az 
I. táblázatban hasonlítottuk össze a makrofág mannóz re-
ceptorok jellemzőivel. A két struktúra hasonlóságot mutat 
a sejtfelszíni kötőhely szám, a disszociációs állandó, pro-
teolítikus emésztésre való érzékenység és a Ca2* függőség 
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Humán keratinocita mannóz kötő receptorok 
és makrofág mannóz receptorok jellemzőinek 
összefoglalása 
juttatják a sejt belsejébe, hasonló jelenséget a keratinoci-
ták esetén nem tudtunk megfigyelni. Az a tény, hogy a 
makrofág mannóz receptor ellenes monoklonális antitest 
nem festette a keratinocitákat, szintén amellett foglal ál-
lást, hogy a keratinociták felszínén lévő mannóz kötő 
struktúrák különböznek a makrofág mannóz receptortól. 
Mannóz kötő képességgel sok ún. C-típusú, kálcium de-
pendens lektin rendelkezik. Amíg a C-típusú lektinek 
nagy része egy egyedüli szénhidrát kötőhellyel (domain) 
rendelkezik (12), az ismert receptoroknak vagy 8 (makro-
fág mannóz és foszfolipáz A2 receptorok) (S, 21) vagy 10 
(DEC 205 receptor) (6) lektin domainje van, és valószínű-
leg ezek együttműködnek egymással, hogy a ligand kötést 
elősegítsék (19, 20). Mindhárom említett receptor rendel-
kezik különböző endocitotikus folyamatokat mediáló ké-
pességgel (3, 17). Eredményeink azt sugallják, hogy a a 
keratinocita mannóz kötő receptorok valószínűleg nem az 
endocitotikus jellegű C-típusú lektinek csoportjának tagja. 
Bár adataink azt mutatják, hogy a keratinociták mannóz 
kötő receptorai aktív szerepet játszanak a Candida ölő 
aktivitásban, tekintettel a makrofágok és keratinociták 
mannóz kötő receptorai közti különbségre, az ölő mecha-
nizmus nem teljesen azonos módon megy végbe. 
További vizsgálatok elvégzése szükséges ahhoz, hogy 
felderítsük a keratinocita Candida ölő funkciójának pon-
tos mechanizmusát. 
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